Kenneth C. Anderson

Kenneth C. Anderson 's AcademicInfluence.com Rankings

Kenneth C. Anderson

Medical

#391

World Rank

#548

Historical Rank

Hematology

World Rank

Historical Rank

Oncology

#11

World Rank

#12

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Kenneth C. Anderson Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Kenneth C. Anderson is an American hematologist-oncologist and cancer researcher who is primarily known for advances in the treatment of multiple myeloma. He directs the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana–Farber Cancer Institute and is the Kraft Family Professor of Medicine and Vice Chair of the Joint Program in Transfusion Medicine at Harvard Medical School.

(See a Problem?)

Kenneth C. Anderson 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) (2949)
A phase 2 study of bortezomib in relapsed, refractory myeloma. (2003) (2631)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc (2011) (2474)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
International uniform response criteria for multiple myeloma (2006) (2014)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (2005) (1965)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. (2008) (1407)
Initial genome sequencing and analysis of multiple myeloma (2011) (1385)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. (2015) (1274)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. (2015) (1072)
High-throughput oncogene mutation profiling in human cancer (2007) (1041)
Lenalidomide after stem-cell transplantation for multiple myeloma. (2012) (1028)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007) (885)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (2011) (862)
NF-κB as a Therapeutic Target in Multiple Myeloma* (2002) (854)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010) (813)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors (2011) (801)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. (2002) (801)
Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease (2002) (781)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma (2017) (776)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells (2002) (769)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma (2014) (743)
Multiple myeloma: increasing evidence for a multistep transformation process. (1998) (738)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. (2003) (730)
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. (1984) (722)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. (2002) (670)
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. (2014) (666)
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. (2013) (664)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. (2005) (661)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. (2004) (652)
Advances in biology of multiple myeloma: clinical applications. (2004) (623)
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells (2003) (613)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. (2006) (609)
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. (1996) (603)
Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer (2009) (595)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. (2005) (593)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. (2003) (589)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. (2016) (582)
Proteasome inhibition as a novel therapeutic target in human cancer. (2005) (570)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. (2004) (570)
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. (2001) (549)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy (2011) (521)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. (2012) (521)
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. (1983) (520)
International uniform response criteria for multiple myeloma (2006) (519)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. (2007) (515)
Multiple myeloma (2017) (514)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. (2006) (511)
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma (2001) (505)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. (2006) (494)
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. (2002) (493)
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications (2002) (491)
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. (2012) (466)
NF-kappa B as a therapeutic target in multiple myeloma. (2002) (464)
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. (1993) (459)
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. (2007) (453)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. (2017) (441)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma (2002) (440)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. (2008) (435)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. (2005) (431)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. (2001) (421)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. (2009) (419)
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. (2006) (416)
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. (2011) (406)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications (2001) (404)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. (2007) (403)
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. (1997) (402)
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. (2002) (395)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. (2007) (395)
The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis (2007) (387)
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. (1999) (371)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis (2017) (369)
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. (2010) (365)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. (2006) (360)
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. (2011) (356)
Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence (2019) (350)
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. (2006) (349)
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. (2009) (347)
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. (2013) (347)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. (2014) (339)
History of the development of arsenic derivatives in cancer therapy. (2001) (336)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. (2014) (336)
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. (2005) (334)
Bone marrow microenvironment and the identification of new targets for myeloma therapy (2009) (332)
Antimyeloma activity of heat shock protein-90 inhibition. (2005) (327)
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. (2005) (326)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. (2013) (322)
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia (2009) (321)
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. (2009) (320)
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. (2017) (320)
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. (1998) (319)
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. (2014) (318)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application (2005) (317)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (2019) (316)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (2019) (316)
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. (2011) (313)
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. (1984) (312)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. (2003) (309)
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. (2010) (306)
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. (1997) (302)
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline (2009) (300)
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. (2013) (299)
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. (2015) (293)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. (2006) (291)
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity (2010) (291)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells (2011) (289)
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (2013) (289)
Hairy cell leukemia: a tumor of pre-plasma cells. (1985) (288)
Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. (1987) (285)
Targeting the bone marrow microenvironment in multiple myeloma (2015) (283)
Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. (1992) (280)
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (2018) (279)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. (2004) (279)
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. (2003) (268)
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. (2014) (266)
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (2018) (266)
Pathogenesis of myeloma. (2011) (263)
Prognostic significance of copy-number alterations in multiple myeloma. (2009) (261)
NCCN clinical practice guidelines in oncology: multiple myeloma. (2009) (260)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (2007) (259)
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. (2009) (259)
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. (2009) (257)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. (2018) (254)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. (2007) (253)
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. (1996) (252)
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma (2008) (251)
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib (2005) (250)
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. (2008) (248)
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma (2011) (245)
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. (2003) (244)
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. (2013) (242)
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma (2015) (242)
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. (2014) (239)
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (2009) (239)
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. (2003) (238)
Dysfunctional T regulatory cells in multiple myeloma. (2006) (236)
RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS (2014) (235)
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. (1996) (233)
Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. (2004) (232)
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies (2001) (231)
Response patterns of purified myeloma cells to hematopoietic growth factors. (1989) (227)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. (2003) (226)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. (2006) (224)
Bortezomib in recurrent and/or refractory multiple myeloma (2005) (223)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. (2013) (221)
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. (2009) (220)
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. (2016) (220)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. (2009) (219)
Lenalidomide and thalidomide: mechanisms of action--similarities and differences. (2005) (217)
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop (2013) (216)
JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells* (2003) (215)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. (2019) (213)
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence (2012) (211)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease (2010) (210)
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. (2006) (210)
Latest advances and current challenges in the treatment of multiple myeloma (2012) (206)
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. (2011) (204)
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. (2009) (203)
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. (2007) (203)
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. (2003) (203)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. (2009) (202)
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. (2017) (202)
Clinically relevant end points and new drug approvals for myeloma (2008) (201)
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. (2007) (201)
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. (2012) (199)
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. (2011) (199)
CD40 ligand triggered interleukin-6 secretion in multiple myeloma. (1995) (197)
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. (2010) (196)
Antigens on human plasma cells identified by monoclonal antibodies. (1983) (196)
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. (1998) (196)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. (2018) (195)
Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma (2007) (194)
The proteasome and proteasome inhibitors in multiple myeloma (2017) (192)
Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. (2009) (192)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. (2019) (191)
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. (2000) (191)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo (2009) (189)
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma (2006) (189)
Cytokines modulate telomerase activity in a human multiple myeloma cell line. (2002) (189)
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. (2008) (187)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma (2008) (186)
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. (2004) (185)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy (2018) (184)
Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017) (183)
Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients (2013) (183)
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study (2008) (180)
Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein (2003) (180)
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo (2003) (180)
Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. (1990) (180)
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. (2014) (180)
Multiple myeloma (2009) (178)
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma (2003) (177)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. (2005) (177)
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth (2013) (175)
Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism (1997) (175)
Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. (1991) (175)
Focus on multiple myeloma. (2004) (175)
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. (2012) (173)
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. (2006) (172)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma (2017) (172)
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide (2016) (172)
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. (2009) (172)
The development of a model for the homing of multiple myeloma cells to human bone marrow. (1997) (170)
Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays (2002) (170)
New drugs for myeloma. (2007) (170)
Extended rituximab therapy in Waldenström's macroglobulinemia. (2005) (170)
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. (2005) (169)
Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation* (2001) (168)
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. (2010) (168)
Current treatment landscape for relapsed and/or refractory multiple myeloma (2015) (166)
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) (165)
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. (2013) (164)
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. (2009) (164)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. (2009) (164)
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. (2006) (164)
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. (2005) (163)
WIP is a chaperone for Wiskott–Aldrich syndrome protein (WASP) (2007) (163)
Proteasome inhibitor therapy in multiple myeloma (2005) (163)
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells (2007) (162)
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. (2004) (162)
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. (2004) (161)
Characterization of adhesion molecules on human myeloma cell lines. (1992) (160)
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. (2008) (159)
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. (2014) (159)
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. (2002) (158)
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. (2003) (157)
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. (2005) (156)
Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. (1986) (156)
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma (2010) (155)
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. (2002) (155)
Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells* (2003) (154)
Genomic landscape and chronological reconstruction of driver events in multiple myeloma (2018) (153)
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). (2004) (153)
Identification of genes modulated in multiple myeloma using genetically identical twin samples. (2004) (151)
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. (2011) (150)
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. (2004) (150)
Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. (1997) (145)
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. (2005) (145)
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. (2007) (144)
Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. (1992) (144)
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. (2007) (143)
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. (2007) (143)
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. (2009) (143)
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. (2006) (142)
Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus-host disease. (1991) (142)
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells (2004) (141)
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. (2010) (141)
Thalidomide: emerging role in cancer medicine. (2002) (140)
A novel proteasome inhibitor NPI-0052 as an anticancer therapy (2006) (140)
Multiple myeloma: biology of the disease. (2010) (140)
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. (2003) (140)
CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications (2002) (139)
Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw (2008) (139)
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. (2004) (138)
Mcl-1 Regulation and Its Role in Multiple Myeloma (2004) (138)
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. (2013) (136)
Targeting B-cell maturation antigen in multiple myeloma. (2015) (135)
Genomic patterns of progression in smoldering multiple myeloma (2018) (135)
Lenalidomide enhances anti-myeloma cellular immunity (2012) (135)
Proteasome inhibition in multiple myeloma: therapeutic implication. (2005) (134)
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting (2018) (133)
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. (2010) (133)
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. (2016) (133)
Thalidomide and rituximab in Waldenstrom macroglobulinemia. (2004) (133)
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. (2015) (132)
Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. (1991) (132)
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia (2010) (132)
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. (2004) (131)
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers (2011) (131)
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. (2004) (130)
Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model (2007) (129)
Association of response endpoints with survival outcomes in multiple myeloma (2013) (129)
BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics (2015) (127)
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. (2007) (127)
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. (2002) (127)
Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? (2009) (127)
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. (2012) (127)
How I treat plasma cell leukemia. (2012) (126)
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. (2003) (126)
Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia (2009) (125)
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. (2007) (125)
Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma: (2006) (125)
A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function (2011) (125)
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. (2002) (125)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo (2010) (125)
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. (2011) (123)
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. (2004) (123)
Guidelines for blood utilization review (1994) (123)
Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. (2002) (123)
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. (2005) (123)
New Strategies in the Treatment of Multiple Myeloma (2013) (122)
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. (2012) (122)
Bortezomib: proteasome inhibition as an effective anticancer therapy. (2006) (122)
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. (2007) (121)
Progress and Paradigms in Multiple Myeloma (2016) (121)
Leukocyte reduction in blood component therapy. (1992) (121)
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma (2014) (120)
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia (2001) (120)
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. (2003) (119)
A clinically relevant SCID-hu in vivo model of human multiple myeloma. (2004) (118)
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. (2017) (118)
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. (2003) (118)
RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells (1999) (117)
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. (2012) (117)
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). (2006) (116)
Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients (1995) (116)
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. (1993) (116)
Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. (2006) (115)
Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial) (2015) (115)
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth (2017) (115)
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. (2009) (115)
Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. (1993) (114)
MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (114)
Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma (2007) (114)
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma (2012) (114)
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. (2003) (113)
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. (2009) (113)
High-dose gallium imaging in lymphoma. (1983) (113)
Telomerase Inhibition and Cell Growth Arrest After Telomestatin Treatment in Multiple Myeloma (2004) (112)
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. (2020) (112)
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells (2007) (112)
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma (2009) (112)
Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. (1990) (112)
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (2008) (111)
PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo (2011) (111)
Proteasome Inhibition in the Treatment of Cancer (2005) (111)
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. (2007) (110)
Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage (1996) (110)
Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia (2010) (110)
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. (2003) (110)
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. (2014) (110)
Minor clone provides a reservoir for relapse in multiple myeloma (2013) (109)
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study (2011) (109)
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. (2009) (109)
Thalidomide and lenalidomide: Mechanism-based potential drug combinations (2008) (109)
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. (2005) (108)
Reducing the risk for transfusion-transmitted cytomegalovirus infection. (1992) (108)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition (2010) (108)
Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. (1985) (108)
The bone-marrow niche in MDS and MGUS: implications for AML and MM (2018) (107)
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. (2010) (107)
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub (2020) (107)
Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia (2016) (107)
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells (2004) (107)
Monoclonal gammopathy of undetermined significance: a consensus statement (2010) (107)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma (2021) (107)
Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. (1996) (106)
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. (2010) (106)
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma (2005) (106)
Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. (1993) (105)
Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment (2004) (105)
Novel therapeutic approaches for multiple myeloma (2003) (104)
Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. (1982) (104)
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells (2011) (104)
Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib * (2006) (104)
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. (2002) (103)
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. (2005) (103)
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo (2015) (103)
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma (2005) (102)
Targeting NF-kappaB in Waldenstrom macroglobulinemia. (2008) (101)
Salvage second hematopoietic cell transplantation in myeloma. (2013) (101)
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. (2013) (100)
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo (2008) (100)
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. (1999) (100)
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. (2003) (99)
Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Transfusion Practices Committee of the American Association of Blood Banks. (1990) (99)
High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties (2009) (99)
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. (2014) (99)
Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma (2008) (98)
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies (2005) (98)
Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. (1996) (98)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. (2003) (97)
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. (2005) (97)
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma (2018) (97)
The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. (2000) (96)
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. (2007) (96)
Novel therapeutic strategies for multiple myeloma. (2015) (96)
Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma (2005) (96)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. (2020) (95)
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. (2017) (95)
Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. (1992) (94)
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups (2017) (94)
Transfusion-related sepsis after prolonged platelet storage. (1986) (94)
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma (2008) (93)
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma (2016) (93)
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. (2009) (93)
Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma (2006) (91)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set (2020) (91)
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back (2014) (91)
Bortezomib in the front-line treatment of multiple myeloma (2008) (91)
Interleukin-6 Overcomes p21WAF1 Upregulation and G1 Growth Arrest Induced by Dexamethasone and Interferon-γ in Multiple Myeloma Cells (1997) (90)
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. (2008) (90)
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma (2017) (90)
MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. (1997) (90)
A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. (1984) (90)
The malignant clone and the bone-marrow environment. (2007) (89)
CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. (1997) (89)
Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (2004) (89)
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. (2002) (89)
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. (2002) (88)
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. (2002) (88)
Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment (2007) (88)
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. (2016) (88)
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. (2003) (87)
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. (2004) (87)
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. (2004) (87)
Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. (2004) (86)
Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104 (2010) (85)
Moving disease biology from the lab to the clinic (2003) (85)
Bortezomib as an antitumor agent. (2006) (85)
Novel therapies for multiple myeloma (2003) (85)
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. (2015) (85)
Individualizing treatment of patients with myeloma in the era of novel agents. (2008) (85)
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells (2015) (84)
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. (2011) (84)
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. (2003) (84)
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. (2011) (84)
Interleukin‐6 in multiple myeloma and related plasma cell dyscrasias (1998) (84)
Promising therapies in multiple myeloma. (2015) (84)
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. (2013) (83)
Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. (1993) (83)
The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival (2015) (83)
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma (2016) (83)
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab (2019) (83)
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. (2019) (82)
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process (1998) (81)
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. (2004) (81)
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma (2004) (81)
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. (2003) (81)
Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering (1996) (80)
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. (2010) (80)
Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity (2012) (80)
Identification and validation of novel therapeutic targets for multiple myeloma. (2005) (80)
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. (2011) (80)
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. (2009) (80)
Inhibition of USP10 induces degradation of oncogenic FLT3. (2017) (80)
Cell surface expression and functional significance of adhesion molecules on human myeloma‐derived cell lines (1994) (80)
Blood Banking and Transfusion Medicine: Basic Principles and Practice (2006) (78)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. (2010) (78)
Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma (2007) (78)
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors (2018) (78)
Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines (2003) (78)
Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. (1999) (77)
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma (2010) (77)
Characterization of reactions after exclusive transfusion of white cell‐ reduced cellular blood components (1995) (77)
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study (2008) (77)
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. (2000) (77)
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. (2008) (77)
The emerging role of novel therapies for the treatment of relapsed myeloma. (2007) (77)
Timing the initiation of multiple myeloma (2019) (76)
Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib (2009) (76)
New Proteasome Inhibitors in Myeloma (2012) (76)
Monoclonal antibodies in the treatment of multiple myeloma (2011) (75)
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. (2018) (75)
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. (2012) (74)
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study (2010) (74)
TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes. (2004) (74)
Emerging therapies for the treatment of relapsed or refractory multiple myeloma (2011) (74)
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. (2000) (74)
Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. (2002) (74)
MUC1-C drives MYC in multiple myeloma. (2016) (74)
Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders (2012) (73)
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect (2003) (73)
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. (2016) (73)
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. (2003) (73)
B5, a new B cell-restricted activation antigen. (1985) (72)
CD40 ligand triggers interleukin-6 mediated B cell differentiation. (1996) (72)
Emerging Therapies for Multiple Myeloma (2006) (71)
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. (2000) (71)
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. (2007) (71)
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications (2017) (71)
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma (2011) (71)
Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma (2012) (70)
Body Mass Index, Physical Activity, and Risk of Multiple Myeloma (2007) (70)
Proteasome inhibition (2004) (70)
Adenovirus vector-based purging of multiple myeloma cells. (1998) (70)
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells (2013) (70)
Thalidomide and immunomodulatory drugs as cancer therapy. (2002) (70)
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. (2004) (70)
In vivo anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor (2008) (69)
Immunotherapeutic strategies for the treatment of plasma cell malignancies. (2000) (69)
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma (2007) (69)
Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM) (2011) (69)
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. (2008) (68)
Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia (2008) (68)
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. (2008) (68)
Proteasome inhibition in hematologic malignancies (2004) (68)
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias (2013) (68)
Multiple myeloma, version 1.2013. (2013) (68)
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells (2011) (68)
Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells* (2004) (68)
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. (2012) (67)
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. (2015) (67)
Bortezomib: a novel therapy approved for multiple myeloma. (2003) (67)
The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma (2015) (67)
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. (2016) (67)
Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. (2001) (67)
Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. (1999) (66)
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant (2020) (65)
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. (2006) (65)
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival (2017) (65)
Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study (2008) (65)
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations (2015) (65)
Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation (2005) (65)
Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. (2006) (65)
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. (2013) (65)
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. (2009) (64)
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. (1999) (64)
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. (2014) (64)
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications (2011) (64)
Monoclonal Antibody-Purged Autologous Bone Marrow Transplantation Therapy for Multiple Myeloma (1991) (64)
Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy (2008) (64)
Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. (2000) (64)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma (2009) (64)
GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. (2012) (64)
Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment (2011) (64)
Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial (2015) (63)
A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells (2016) (63)
Heat Shock Protein 90 Is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells (2013) (63)
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway (2005) (63)
MYD 88 L 265 P in Waldenström macroglobulinemia , immunoglobulin M monoclonal gammopathy , and other B-cell lymphoproliferative disorders using conventional and quantitative allele-speci fi c polymerase chain reaction (2013) (63)
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo (2009) (62)
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. (2018) (62)
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma [see comments] (1994) (62)
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. (2011) (62)
Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. (1997) (62)
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma (2020) (61)
Kidney disease associated with plasma cell dyscrasias. (2010) (61)
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. (2016) (61)
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). (2016) (61)
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells (2003) (61)
BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity (2012) (61)
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI‐0052 (marizomib) in a human plasmacytoma xenograft murine model (2010) (61)
Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma (2010) (61)
Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT) (2013) (60)
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis (2019) (60)
T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. (1990) (60)
Interleukin-11 promotes accessory cell-dependent B-cell differentiation in humans. (1992) (60)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. (2019) (60)
A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma (2004) (59)
B protein of factor XIII: differentiation between free B and complexed B. (1988) (59)
A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. (2019) (59)
Phase transitions in human IgG solutions. (2013) (59)
Multiple Myeloma: New Insights and Therapeutic Approaches. (2000) (59)
Role of interleukin 6 in the growth of myelomaderived cell lines (1992) (59)
Multiple myeloma. Clinical practice guidelines in oncology. (2007) (59)
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) (58)
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. (2005) (58)
AACR Cancer Progress Report 2013 (2013) (58)
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma (2020) (58)
Intracellular Protein Degradation and Its Therapeutic Implications (2005) (58)
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. (2013) (58)
Proteomic analysis of waldenstrom macroglobulinemia. (2007) (58)
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation (2014) (58)
Differential and limited expression of mutant alleles in multiple myeloma. (2014) (58)
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study (2012) (58)
Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine (2001) (57)
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells (2017) (57)
Proteasome inhibitor drugs on the rise. (2006) (57)
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study (2015) (57)
p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications (2008) (57)
Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage1 (2000) (57)
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells (1995) (57)
Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma (2015) (57)
Anti-estrogens induce apoptosis of multiple myeloma cells. (1998) (57)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide (2011) (57)
HEPATIC DYSFUNCTION FOLLOWING T‐CELL-DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION (1991) (56)
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341 (2004) (56)
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications (2017) (56)
Blood Banking and Transfusion Medicine (2002) (56)
Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment (2008) (56)
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. (2015) (56)
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. (2019) (56)
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies (2007) (55)
Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma (2014) (55)
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. (2007) (55)
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside (2016) (55)
A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. (2016) (55)
A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients (2014) (55)
Pyk2 promotes tumor progression in multiple myeloma. (2014) (55)
Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies (2007) (55)
Multiple myeloma. (2011) (55)
B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma (2019) (54)
Novel biological therapies for the treatment of multiple myeloma. (2005) (54)
Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone (1999) (54)
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. (2005) (53)
Daratumumab granted breakthrough drug status (2014) (53)
Minimal residual disease in multiple myeloma. (2013) (53)
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. (2018) (53)
Recombinant humanized anti‐CD40 monoclonal antibody triggers autologous antibody‐dependent cell‐mediated cytotoxicity against multiple myeloma cells (2003) (53)
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth (2016) (53)
Antibody-Based Therapies in Multiple Myeloma (2011) (52)
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth (2007) (52)
Viral antigen‐specific CD8+ T‐cell responses are impaired in multiple myeloma (2003) (52)
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications (2018) (52)
Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. (1987) (52)
Targeting proteasomes as therapy in multiple myeloma. (2008) (51)
Cytokines and signal transduction. (2005) (51)
Revealing the impact of structural variants in multiple myeloma. (2020) (51)
Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. (2000) (51)
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. (2020) (51)
Significant Biological Role of Sp1 Transactivation in Multiple Myeloma (2011) (50)
Autologous peripheral blood progenitor cell transplantation (1995) (50)
Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience (2008) (50)
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity (2018) (50)
Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. (2006) (50)
Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia. (1991) (50)
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma (2015) (50)
Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM). (2004) (50)
Role of cytokines in multiple myeloma. (1999) (49)
Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells. (1995) (49)
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial (2020) (49)
Advances in disease biology: Therapeutic implications (2001) (49)
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. (2022) (49)
From the bench to the bedside: emerging new treatments in multiple myeloma (2007) (49)
Immune Therapies in Multiple Myeloma (2016) (49)
Isolation and characterization of human multiple myeloma cell enriched populations. (2000) (49)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. (2010) (48)
Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. (2018) (48)
The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. (1998) (48)
Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs (2013) (48)
New insights into therapeutic targets in myeloma. (2011) (48)
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors (2005) (48)
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma (2019) (48)
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. (2003) (48)
Novel biologically based therapies for Waldenstrom's macroglobulinemia. (2003) (48)
Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib (2014) (48)
Cellular adhesion molecules. (1994) (47)
Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias (2009) (47)
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. (2013) (47)
Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma (2016) (47)
Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma (2012) (47)
Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial (2011) (47)
Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. (1991) (47)
Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell (2007) (47)
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. (2008) (47)
Proteasome inhibition as a new therapeutic principle in hematological malignancies. (2006) (47)
The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells (2015) (47)
Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. (2014) (46)
Lack of a role of interleukin 11 in the growth of multiple myeloma. (1992) (46)
Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells (2018) (46)
Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma (2011) (46)
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications (2016) (46)
Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma (2017) (46)
Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial (2011) (46)
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. (1999) (46)
Immunologic heterogeneity of diffuse large cell lymphoma. (1985) (46)
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells (2020) (46)
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications. (2002) (46)
Indications and guidelines for the use of hematopoietic growth factors (1993) (45)
Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial (2011) (45)
Anti‐B4‐blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma (1998) (45)
Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. (1993) (45)
MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. (2008) (45)
Novel therapies in the treatment of multiple myeloma. (2009) (45)
A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma. (2014) (44)
Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. (1993) (44)
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells (2016) (44)
Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. (2012) (44)
SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads (2018) (44)
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. (2012) (44)
A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA. (1992) (44)
BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (2011) (44)
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. (2006) (44)
Accelerating anticancer drug development — opportunities and trade-offs (2018) (44)
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma (2017) (43)
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. (2012) (43)
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma (2007) (43)
Synergistic anti‐myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide (2015) (42)
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling (2019) (42)
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1 (2018) (42)
Advances in the biology of multiple myeloma: therapeutic applications. (1999) (42)
The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation. (2002) (42)
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma. (2008) (42)
A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma (2008) (41)
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. (2012) (41)
Multiple myeloma: the (r)evolution of current therapy and a glance into future. (2020) (41)
A SCID-hu in vivo model of human Waldenström macroglobulinemia. (2005) (41)
BH 3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH 3 mimetics (2019) (41)
JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. (2020) (41)
Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. (1989) (40)
Transfusion-associated graft-versus-host disease. (1991) (40)
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial (2010) (40)
Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma (2009) (40)
A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM). (2006) (40)
Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma (2018) (40)
Perspectives for combination therapy to overcome drug-resistant multiple myeloma. (2005) (40)
Targeting the UPS as therapy in multiple myeloma (2008) (39)
Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. (2009) (39)
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. (2009) (39)
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing (2018) (39)
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients (2016) (39)
Bone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study (2015) (39)
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations (2021) (39)
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias (2001) (39)
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. (2010) (39)
The treatment of relapsed and refractory multiple myeloma. (2007) (39)
Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity. (2007) (39)
Nucleotide excision repair is a potential therapeutic target in multiple myeloma (2017) (38)
A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma. (2005) (38)
Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. (1997) (38)
Intracellular NAD+ depletion induces autophagic death in multiple myeloma cells (2013) (38)
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma (2008) (38)
Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. (2004) (38)
Management of myeloma-associated renal dysfunction in the era of novel therapies (2012) (37)
A novel immunogenic CS1‐specific peptide inducing antigen‐specific cytotoxic T lymphocytes targeting multiple myeloma (2012) (37)
Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284) (2006) (37)
Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. (1999) (37)
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. (2004) (37)
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma (2020) (37)
The role of immunomodulatory drugs in multiple myeloma. (2003) (37)
CCR1 as a target for multiple myeloma (2011) (37)
Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2014) (37)
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. (2011) (37)
Current therapeutic uses of lenalidomide in multiple myeloma (2006) (37)
Hairy cell leukemia: a tumor of pre-plasma cells (1985) (37)
Arsenic Trioxide in Multiple Myeloma: Rationale and Future Directions (2002) (36)
Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. (1989) (36)
Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsets. (1985) (36)
Scientific Basis of Transfusion Medicine: Implications for Clinical Practice (1994) (36)
Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients (2005) (36)
Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients (2013) (36)
Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients (2005) (36)
Telomere Maintenance in Laser Capture Microdissection–Purified Barrett's Adenocarcinoma Cells and Effect of Telomerase Inhibition In vivo (2008) (36)
Role of interleukin 6 in the growth of myeloma-derived cell lines. (1992) (36)
Management of multiple myeloma today. (1999) (36)
Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy (2012) (36)
Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. (1991) (35)
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. (2017) (35)
Deciphering the chronology of copy number alterations in Multiple Myeloma (2019) (35)
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs (2005) (35)
Lenalidomide in multiple myeloma (2006) (35)
Risks, costs, and alternatives to platelet transfusions. (1999) (35)
Functional significance of novel neurotrophin‐1/B cell‐stimulating factor‐3 (cardiotrophin‐like cytokine) for human myeloma cell growth and survival (2003) (35)
Targeting proteasome inhibition in hematologic malignancies. (2003) (35)
Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail. (2005) (35)
Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial (2014) (35)
A pilot study of combined immunotherapy with autologous adoptive tumour‐specific T‐cell transfer, vaccination with CD40‐activated malignant B cells and interleukin 2 (2001) (35)
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide (2014) (35)
A novel panel of protein biomarkers for predicting response to thalidomide‐based therapy in newly diagnosed multiple myeloma patients (2011) (35)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set (2020) (35)
The evolution and impact of therapy in multiple myeloma (2010) (35)
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma (2006) (35)
Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma (2008) (35)
Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. (1984) (34)
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study. (2007) (34)
Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. (1997) (34)
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation (1997) (34)
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma (2020) (34)
β-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells (2002) (33)
Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies. (1996) (33)
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation (2015) (33)
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma (2019) (33)
CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. (1997) (33)
Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’ (2018) (33)
JS‐K has potent anti‐angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo (2010) (33)
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma (2018) (33)
MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM) (2013) (33)
What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? (2002) (33)
Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation (1994) (33)
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. (2005) (33)
Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib (2008) (32)
Multiple myeloma: how far have we come? (2003) (32)
Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia (2011) (32)
A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). (2001) (32)
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. (2012) (32)
Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation. (2014) (32)
Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma (2004) (32)
p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. (1997) (32)
Targeting signalling pathways for the treatment of multiple myeloma (2005) (32)
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. (2002) (32)
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up (2015) (32)
Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial. (2005) (32)
In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 Against Multiple Myeloma Cells (2011) (32)
Bruton's tyrosine kinase: oncotarget in myeloma (2012) (32)
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. (2017) (32)
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways (2020) (31)
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. (2010) (31)
Drug Insight: thalidomide as a treatment for multiple myeloma (2005) (31)
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? (2014) (31)
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma (2020) (31)
Pathological crystallization of human immunoglobulins (2012) (31)
Who benefits from high-dose therapy for multiple myeloma? (1995) (31)
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma (2015) (31)
Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma (2008) (31)
Interleukin‐6 is Required for Pristane‐Induced Plasma Cell Hyperplasia In Mice (1996) (31)
Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM (2014) (31)
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study. (2007) (31)
Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. (2002) (31)
Lenalidomide for the treatment of relapsed and refractory multiple myeloma (2012) (31)
The heavy chain diseases: clinical and pathologic features. (2014) (30)
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. (2001) (30)
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. (2003) (30)
International uniform response criteria for multiple myeloma (2007) (30)
Melflufen - a peptidase-potentiated alkylating agent in clinical trials (2017) (30)
Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation. (2007) (30)
Future agents and treatment directions in multiple myeloma (2014) (30)
Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up (2010) (30)
Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma (2017) (30)
Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation (2011) (30)
Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM). (2009) (30)
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study (2018) (30)
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents (2012) (30)
Novel epitope evoking CD138 antigen‐specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders (2011) (29)
P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells. (2004) (29)
Tanespimycin as antitumor therapy. (2011) (29)
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. (2020) (29)
Histone deacetylase inhibitors in the treatment for multiple myeloma (2013) (29)
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. (1994) (29)
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma (2009) (29)
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease (2014) (29)
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma (2019) (29)
In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465 (2009) (29)
Comparison of twin and autologous transplants for multiple myeloma. (2008) (29)
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. (2016) (29)
Role of liposomal anthracyclines in the treatment of multiple myeloma. (2004) (29)
Human B Cell-Associated Antigens: Expression on Normal and Malignant B Lymphocytes (1984) (29)
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (2017) (29)
Bone marrow transplantation in multiple myeloma. (1997) (28)
Identification of upstream signals regulating interleukin-6 gene expression during in vitro treatment of human B cells with pokeweed mitogen. (1994) (28)
The power of proteasome inhibition in multiple myeloma (2018) (28)
Proteasome inhibitors as therapeutics. (2005) (28)
Apoptotic Signaling in Multiple Myeloma: Therapeutic Implications (2003) (28)
The biological significance of histone modifiers in multiple myeloma: clinical applications (2018) (28)
Novel therapies in myeloma (2007) (28)
Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma (2014) (28)
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies. (2012) (28)
Mouse models of human myeloma. (2007) (28)
Broadening the spectrum of patient groups at risk for transfusion‐associated GVHD: implications for universal irradiation of cellular blood components (2003) (28)
Melflufen - a peptidase-potentiated alkylating agent in clinical trials. (2017) (28)
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia (2009) (28)
Caveolin-1 as a potential new therapeutic target in multiple myeloma. (2006) (27)
Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. (1999) (27)
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group (2020) (27)
Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells. (1984) (27)
Therapeutic advances in relapsed or refractory multiple myeloma. (2013) (27)
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma (2018) (27)
New treatments for multiple myeloma. (2005) (27)
Thalidomide in multiple myeloma. (2002) (27)
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma (2017) (26)
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. (2015) (26)
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (2011) (26)
PI3K/p110 is a novel therapeutic target in multiple myeloma (2011) (26)
Targeted therapy for multiple myeloma. (2001) (26)
Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM) (2008) (26)
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway (2007) (26)
A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy. (2005) (26)
Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2016) (26)
Novel therapies in MM: from the aspect of preclinical studies (2011) (26)
Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma (2014) (25)
A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (2008) (25)
Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte‐colony‐stimulating factor: implications for yield of hematopoietic progenitor cell collections (1996) (25)
Proteasome inhibitors in multiple myeloma. (2009) (25)
Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma. (2007) (25)
Best treatment strategies in high-risk multiple myeloma: navigating a gray area. (2014) (25)
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma (2007) (25)
Regulation of c-jun gene expression in human T lymphocytes. (1993) (25)
Moving disease biology from the laboratory to the clinic. (2002) (25)
Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug (2001) (25)
From the bench to the bedside: emerging new treatments in multiple myeloma. (2007) (25)
Risks of cancer among a cohort of 23,935 men and women with osteoporosis (2007) (25)
Novel biologically based therapies for myeloma. (2001) (25)
Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma (2015) (25)
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma (2020) (25)
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. (2009) (25)
The impact of response kinetics for multiple myeloma in the era of novel agents. (2019) (24)
Telomerase inhibitors as anticancer therapy. (2002) (24)
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1 (2014) (24)
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma (2018) (24)
Molecular and cellular effects of multi‐targeted cyclin‐dependent kinase inhibition in myeloma: biological and clinical implications (2011) (24)
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma (2011) (24)
CSNK1α1 mediates malignant plasma cell survival (2014) (24)
Signaling Pathway Mediating Myeloma Cell Growth and Survival (2021) (24)
Multiple Myeloma. Advances in disease biology: therapeutic implications. (2001) (24)
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells (2012) (23)
A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results. (2005) (23)
Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth. (1996) (23)
MUC1‐C is a target in lenalidomide resistant multiple myeloma (2017) (23)
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era (2017) (23)
Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study. (2004) (23)
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. (2020) (23)
Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation (2012) (23)
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study (2013) (22)
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma (2018) (22)
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status (2016) (22)
Anti-BCMA BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment (2018) (22)
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma (2006) (22)
The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy (2015) (22)
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings (2011) (22)
Hypotensive reactions associated with white cell‐reduced apheresis platelet concentrates in patients not receiving ACE Inhibitors (1998) (22)
Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy (2019) (22)
Preclinical studies of novel targeted therapies. (2007) (22)
A comparison of peripheral blood stem cell apheresis using the Fenwal CS3000 Plus and COBE Spectra. (1995) (22)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. (2022) (21)
Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). (2015) (21)
Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study (2008) (21)
Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma. (2007) (21)
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells (2014) (21)
Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. (2001) (21)
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution (2016) (21)
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells (2006) (21)
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis. (2009) (21)
Plasma Cell Tumors (2003) (21)
Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma (2006) (21)
Bortezomib therapy for myeloma. (2004) (21)
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia (2018) (20)
Preparing the ground for vaccination against multiple myeloma. (2000) (20)
Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma (2017) (20)
ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006). (2012) (20)
Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. (2019) (20)
CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341 (2015) (20)
Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. (2017) (20)
A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma. (2006) (20)
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma (2011) (20)
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx). (2009) (20)
Involvement of serum response element in okadaic acid-induced EGR-1 transcription in human T-cells. (1994) (20)
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients (2010) (20)
Development of effective new treatments for multiple myeloma. (2005) (20)
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci (2016) (20)
Targeting NF-B in Waldenstrom macroglobulinemia (2008) (20)
BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications (2019) (19)
Stem cell transplantation for myeloma. (2004) (19)
Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia (2009) (19)
AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo (2019) (19)
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy (2009) (19)
Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). (2005) (19)
Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells (1999) (19)
Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion. (1983) (19)
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial (2009) (19)
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). (2012) (19)
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma (2017) (19)
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo (2020) (18)
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells (2015) (18)
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. (2010) (18)
Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (2014) (18)
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity (2013) (18)
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β (2008) (18)
ligand-induced apoptosis in human multiple myeloma cells Intracellular regulation of tumor necrosis factor-related apoptosis-inducing (2002) (18)
Hematologic Profiles in the Phase 3 APEX Trial. (2005) (18)
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. (2007) (18)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia (2016) (18)
Management of relapsed and relapsed/refractory multiple myeloma. (2011) (18)
The B Cell-Restricted Glycoprotein (B2) Is the Receptor for Epstein-Barr Virus (1986) (18)
in patients with multiple myeloma Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels (2000) (18)
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution (2007) (18)
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma (2016) (17)
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma (2019) (17)
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma (2021) (17)
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. (2003) (17)
Identification of human leucocyte antigen (HLA)‐A*0201‐restricted cytotoxic T lymphocyte epitopes derived from HLA‐DOβ as a novel target for multiple myeloma (2013) (17)
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). (2019) (17)
Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma (2017) (17)
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma. (2000) (17)
Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib. (2007) (17)
Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. (1990) (17)
Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM). (2006) (17)
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma (2019) (17)
Leukodepleted cellular blood components for prevention of transfusion-associated graft-versus-host disease (1995) (17)
Novel therapeutic avenues in myeloma: changing the treatment paradigm. (2007) (17)
Response patterns of hairy cell leukemia to B-cell mitogens and growth factors (1990) (17)
Final Analysis of Overall Survival from the First Trial (2016) (17)
Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. (2018) (17)
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (2022) (17)
Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity (2008) (16)
Dual fluorochrome analysis of human B lymphocytes: phenotypic examination of resting, anti-immunoglobulin stimulated, and in vivo activated B cells. (1986) (16)
Clinical update: novel targets in multiple myeloma. (2004) (16)
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice (2016) (16)
Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM) (2013) (16)
SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple Myeloma (2014) (16)
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. (2008) (16)
A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism. (1996) (16)
Transplants for multiple myeloma (1995) (16)
Proteasome inhibition as a therapeutic strategy for hematologic malignancies (2005) (16)
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells (2014) (16)
The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. (1990) (16)
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a (2020) (16)
In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells (2006) (16)
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study. (2009) (15)
Meaningful changes in end-of-life care among patients with myeloma (2018) (15)
Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study. (2009) (15)
Velcade and Vitamin C: Too Much of a Good Thing? (2006) (15)
Preparation and utilization of leukocyte poor apheresis platelets (1991) (15)
Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma (2012) (15)
A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. (1994) (15)
Activation signals regulate heat shock transcription factor 1 in human B lymphocytes (1997) (15)
A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2014) (15)
Transfusion‐associated graft‐versus‐host disease: scratching the surface (1993) (15)
NCCN Guidelines Update for Multiple Myeloma. (2016) (15)
Phase II trial of mitoxantrone. (1982) (15)
Treatment of low‐grade and intermediate‐grade lymphoma with intensive combination chemotherapy results in long‐term, disease‐free survival (1990) (15)
Strategies to improve the outcome of stem cell transplantation in multiple myeloma. (2004) (15)
A new era of immune therapy in multiple myeloma. (2016) (15)
Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma (2008) (15)
Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long‐term outcomes and risk of thromboembolic events with use of erythropoiesis‐stimulating agents: analysis of the VISTA trial (2011) (15)
Setting the Standard for Translational Cancer Research (2009) (15)
Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. (2021) (15)
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. (2020) (14)
Novel targeted agents in the treatment of multiple myeloma. (2014) (14)
A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). (2006) (14)
Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib (2013) (14)
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results. (2009) (14)
Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication. (2009) (14)
Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial. (2018) (14)
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration (2021) (14)
High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma (2020) (14)
HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-versus-host disease. (1994) (14)
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. (2016) (14)
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma (2021) (14)
A strategic framework for novel drug development in multiple myeloma (2007) (14)
Multiple myeloma: a clinical overview. (2011) (14)
Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis (2012) (14)
Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening (2008) (14)
Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes (2012) (13)
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma (2017) (13)
Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma (2018) (13)
AMG 701, a half-life extended anti-BCMA BiTE®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment (2019) (13)
MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells. (1998) (13)
The role of the blood bank in hematopoietic stem cell transplantation (1992) (13)
Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) (2008) (13)
Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. (1997) (13)
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events. (2009) (13)
selective HDAC 6 inhibitor , ACY-1215 , in combination with bortezomib in Preclinical activity , pharmacodynamic and pharmacokinetic properties of a (2012) (13)
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma (2007) (13)
Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma (2019) (13)
Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma (2008) (13)
Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. (2011) (13)
Response patterns of hairy cell leukemia to B-cell mitogens and growth factors. (1990) (13)
Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. (2005) (13)
MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma (2019) (13)
RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms (2008) (13)
A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005) (2015) (13)
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (2012) (13)
Monoclonal antibodies: their use in bone marrow transplantation. (1987) (12)
AACR Cancer Progress Report 2016: Improving Lives Through Research (2016) (12)
Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. (2013) (12)
Recent advances in the treatment of Multiple Myeloma. (2006) (12)
Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. (2013) (12)
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. (2014) (12)
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities (2021) (12)
In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation. (1997) (12)
Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma (2010) (12)
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. (2008) (12)
A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results. (2007) (12)
Immunotherapy strategies in multiple myeloma. (2014) (12)
The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. (2021) (12)
Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. (2011) (12)
Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity (2019) (12)
Bacterial Contamination of Platelets (1993) (11)
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. (2021) (11)
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma (2021) (11)
What's Your Line? (2009) (11)
Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis (2010) (11)
The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma (2019) (11)
An update of novel therapeutic approaches for multiple myeloma (2004) (11)
A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM). (2005) (11)
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. (2005) (11)
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. (2009) (11)
Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma (2020) (11)
Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma. (2009) (11)
The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib (2012) (11)
Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience. (2008) (11)
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. (2017) (11)
Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. (2011) (11)
New Frontiers in the Treatment of Multiple Myeloma (2006) (11)
Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma (2016) (11)
AACR Cancer Progress Report 2014: Transforming Lives Through Research (2014) (11)
Emerging drugs in multiple myeloma (2007) (11)
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma (2000) (11)
Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients (2013) (10)
Phase I trial of mitoxantrone by 24-hour continuous infusion. (1983) (10)
Bortezomib in the treatment of multiple myeloma (2011) (10)
Targeting CD38 alleviates tumor-induced immunosuppression (2017) (10)
Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target? (2012) (10)
Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents. (2007) (10)
S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (2019) (10)
PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG ) (2014) (10)
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer (2017) (10)
Novel biologically based therapeutic strategies in myeloma. (2002) (10)
Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma. (2005) (10)
Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers (2014) (10)
Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study. (2009) (10)
Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs (2010) (10)
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma (2021) (10)
Defibrotide (DF) Targets Tumor-Microenvironmental Interactions and Sensitizes Multiple Myeloma and Solid Tumor Cells to Cytotoxic Chemotherapeutics. (2004) (10)
Studies of the in vitro activation and differentiation of human B lymphocytes. II. Optimization of activation by anti-immunoglobulin antibody bound to beads: analysis of the role of autocrine effects on B-cell proliferation and of T-cell help in B-cell differentiation. (1986) (10)
CD 40 induces human multiple myeloma cell migration via phosphatidylinositol 3 – kinase / AKT / NF-B signaling (2003) (10)
Management of Relapsed and Relapsed/Refractory Multiple Myeloma (2011) (10)
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against (2017) (10)
Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia (2010) (10)
A tribute to Jan Gosta Waldenström. (1997) (10)
Novel biologically based therapies for multiple myeloma (2002) (10)
Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1128–350 Triggers MM Cell Death Via c- Jun Upregulation (2012) (10)
SYDNEY E. SALMON, MD (2000) (10)
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma (2022) (10)
A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. (2011) (10)
Multiple myeloma. (2001) (10)
Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma (2015) (10)
Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma (2019) (10)
Combination of the mTOR inhibitor Rapamycin and Revlimid ( CC-5013 ) has synergistic activity in Multiple Myeloma (2004) (10)
A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population (2010) (10)
A 3D‐Bioprinted Multiple Myeloma Model (2021) (10)
Clinical translation in multiple myeloma: from bench to bedside. (2013) (10)
Monoclonal antibody purged autologous bone marrow transplantation for relapsed non i acute lymphoblastic leukemia (1985) (10)
The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo. (2004) (10)
PI 3 K / p 110 is a novel therapeutic target in multiple myeloma (2010) (10)
Should minimal residual disease negativity be the end point of myeloma therapy? (2017) (10)
Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (2010) (10)
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors (2015) (10)
Establishment of a Waldenstrom’s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice. (2005) (9)
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. (2021) (9)
Multiple myeloma: the (r)evolution of current therapy and a glance into the future (2020) (9)
Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM) (2010) (9)
Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). (2017) (9)
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* (2012) (9)
Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of 1-Integrin and Phosphatidylinositol 3-Kinase / AKT Signaling 1 (2003) (9)
Immunotherapeutic and Targeted Approaches in Multiple Myeloma (2020) (9)
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. (2018) (9)
IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity. (2004) (9)
Proteasome inhibitors as therapeutics: Figure 1 (2005) (9)
Bortezomib in the management of multiple myeloma (2009) (9)
Restoration of Bone Balance Via Activin a Inhibition Results in Anti-Myeloma Activity (2008) (9)
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma. (2009) (9)
Promise of Immune Therapies in Multiple Myeloma. (2018) (9)
Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). (2018) (9)
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression (2021) (9)
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. (2001) (9)
CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo (2017) (9)
Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group (2019) (9)
Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels in patients with multiple myeloma (2000) (9)
Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom’s macroglobulinemia, and effect on tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors. (2012) (9)
Novel therapeutic targets in multiple myeloma (2000) (9)
BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (2010) (9)
Role of 99mTc methylene diphosphonate bone imaging in the management of lymphoma. (1985) (9)
Phenotypic and functional characterization of normal and malignant terminal B (plasma) cells (1989) (8)
Activation of pp90rsk and early growth response-1 gene expression by pokeweed mitogen in human B cells. (1995) (8)
Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma. (2006) (8)
Epigenetic modulation in hematologic malignancies: challenges and progress. (2009) (8)
Thalidomide: Therapeutic potential in hematologic malignancies (2000) (8)
Precision medicine in multiple myeloma: are we there yet? (2019) (8)
Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study (2016) (8)
Anti-CD 38-Blocked Ricin : An Immunotoxin for the Treatment of Multiple Myeloma (2002) (8)
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. (2014) (8)
Individuals Expressing FcγRIIIA-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIA (CD16), Rituximab Binding, and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab. (2005) (8)
Hematology: Thalidomide maintenance in multiple myeloma (2009) (8)
Resistance to Proteasome Inhibitors in Multiple Myeloma (2014) (8)
Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (8)
CD45 isoforms associated with distinct functions of CD4 cells derived from unusual healthy donors lacking CD45RA- T lymphocytes. (1991) (8)
Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma (2015) (8)
Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma. (2021) (8)
Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). (2021) (8)
BCMA CAR T-cell therapy arrives for multiple myeloma: a reality. (2018) (8)
Announcing the AACR Cancer Progress Report 2013 (2013) (8)
Current trends: evolving concepts in transfusion medicine. The need for standardization of cryoprecipitate-derived fibrin adhesive. (1993) (8)
Bone marrow transplantation in multiple myeloma. (1999) (8)
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. (2012) (8)
Microrna Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy (2008) (8)
CD 40 activation induces p 53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells (2002) (8)
Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma (2008) (8)
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. (2021) (8)
Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform (2021) (8)
Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM) (2010) (8)
Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (2016) (8)
Deubiquitylating Enzyme USP-7, a Novel Therapeutic Target in Multiple Myeloma. (2009) (8)
Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist. (2018) (8)
Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications. (2006) (8)
Platelet transfusion and alternatives to transfusion in patients with malignancy (1995) (8)
Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study. (2006) (8)
Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury (2020) (8)
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis. (2013) (7)
The evolving background for high-dose treatment for myeloma (2007) (7)
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma. (2009) (7)
Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy (2017) (7)
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery. (2002) (7)
Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
Lack of Response to Vaccination in MGUS and Stable Myeloma. (2009) (7)
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment (2021) (7)
Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma (2008) (7)
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis (2000) (7)
A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (2014) (7)
Cancer clinical trials--do we need a new algorithm in the age of stratified medicine? (2013) (7)
Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT (2012) (7)
ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary. (2007) (7)
Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma. (2006) (7)
Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2008) (7)
Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG. (2004) (7)
Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM). (2004) (7)
Contribution of Inhibition of Protein Catabolism in Myeloma (2019) (7)
Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM) (2017) (7)
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH (2021) (7)
Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. (2013) (7)
Alternate Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A High-Density Exon Array Analysis of Uniformly Treated Newly-Diagnosed Myeloma Patients (2008) (7)
Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma (2017) (7)
Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myeloma. (1999) (7)
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results. (2009) (7)
Emerging trends in the clinical use of bortezomib in multiple myeloma. (2005) (7)
The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome (2018) (6)
B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstrom’s Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion. (2004) (6)
The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. (2018) (6)
Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. (2009) (6)
Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma (2011) (6)
Targeting Bcl-2 as Therapy for Multiple Myeloma. (2005) (6)
Bone marrow transplantation in the therapy of non-Hodgkin's lymphomas. (1986) (6)
Hematologic Complications and Blood Bank Support (2003) (6)
Novel immunomodulatory therapies in the treatment of multiple myeloma. (2004) (6)
An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma (2014) (6)
Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma. (2004) (6)
Autologous bone marrow transplantation therapy for multiple myeloma (1989) (6)
Facts and Hopes in Multiple Myeloma Immunotherapy (2021) (6)
A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia. (2009) (6)
TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. (2004) (6)
An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma. (2009) (6)
Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma (2022) (6)
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma (2022) (6)
Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage. (2006) (6)
Does maintenance therapy with thalidomide benefit patients with multiple myeloma? (2007) (6)
Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure (2012) (6)
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. (2002) (6)
Anti-Myeloma Activity of a Novel Free Radical Inducer Rrx-001 (2014) (6)
YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. (2020) (6)
Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM) (2017) (6)
Rho-a and Rac-1 GTPases Play Major and Differential Roles in SDF1α- Induced Cell Adhesion and Chemotaxis in Multiple Myeloma. (2008) (6)
Introduction: immunotherapy for multiple myeloma--insights and advances. (1999) (6)
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma (2018) (6)
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial (2019) (6)
Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. (2020) (6)
Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom’s Macroglobulinemia. (2006) (6)
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2019) (6)
GM‐CSF mobilized peripheral blood stem cell autografts: The DFCI/BIH experience (1992) (6)
Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib (2010) (6)
ESAs not the culprit: More studies required (2008) (6)
Inhibition of the TGF-β Signaling Pathway in Tumor Cells (2007) (6)
Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib (2020) (6)
The challenge of cross-trial comparisons using limited data (2014) (6)
Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. (2022) (6)
Medical oncologists’ clinical experiences and comfort levels with 20 recently approved agents. (2013) (6)
Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival (2021) (6)
Deubiquitylating Enzyme Rpn11/POH1/PSMD14 As Therapeutic Target in Multiple Myeloma (2016) (6)
Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model. (2009) (6)
Authors’ response to the letter to the Editor from Drs. Kyridis and Triaridis regarding ‘Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients’ (2009) (6)
Are guidelines for use of gamma irradiation for the prevention of transfusion‐associated graft‐versus‐host disease adequate for newborns? (1997) (6)
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma (2022) (5)
Multiple myeloma. (2014) (5)
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). (2013) (5)
Multiple Myeloma: Translational and Emerging Therapies (2007) (5)
Phenotypic Changes Occurring during in vitro Activation of Human Splenic B Lymphocytes (1986) (5)
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13 (2021) (5)
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor (2021) (5)
The safety of current and emerging therapies for multiple myeloma (2020) (5)
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (2019) (5)
IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. (2020) (5)
APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM (2018) (5)
Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis. (2004) (5)
Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia. (1983) (5)
A proto-oncogene BCL 6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells (2010) (5)
Re: When you look matters: the effect of assessment schedule on progression-free survival. (2008) (5)
The myeloma-developing regimens using genomics (MyDRUG) master protocol. (2019) (5)
CS1, a New Surface Target on Multiple Myeloma (MM) Cells, Protects Myeloma Cells from Apoptosis Via Regulation of ERK1/2, AKT and STAT3 Signaling Cascades. (2007) (5)
Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. (2007) (5)
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. (2021) (5)
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13 (2020) (5)
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells (2011) (5)
A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety (2019) (5)
LSD1 Impairs the Epithelial-Mesenchymal Transition (EMT) and Osteoclastogenesis Potency in Multiple Myeloma and Synergistically Induces Cytotoxicity with HDAC Inhibitors (2014) (5)
ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology (2021) (5)
Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare. (2021) (5)
The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma. (2006) (5)
Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications. (2006) (5)
Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker. (2012) (5)
Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia. (2009) (5)
Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma (2011) (5)
Revealing the impact of recurrent and rare structural variants in multiple myeloma (2019) (5)
Thalidomide in hematologic malignancies: Future directions (2000) (5)
A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies. (2004) (5)
MUC 1 oncoprotein promotes growth and survival of human multiple myeloma cells (5)
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma. (2014) (5)
Transfusion support in acute leukemias. (1997) (5)
Multiple Myeloma - a New Era of Treatment Strategies (2012) (5)
Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study (2010) (5)
Targeted Therapy in Translational Cancer Research (2015) (5)
Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease (2008) (5)
Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients (2014) (5)
miR-15a/16-1 deletion in activated B-cells promotes plasma cell and mature B-cell neoplasms. (2020) (5)
A Meta-Analysis Investigating the Impact of Minimal Residual Disease (MRD) Status on Survival Outcomes in Patients With Multiple Myeloma (MM) who Achieve Complete Response (CR) (2015) (5)
CD 6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission (1997) (4)
The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK 787 / ZK 222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment 1 (1998) (4)
Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease (2012) (4)
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (4)
Phase I trial of chir-258 in multiple myeloma. (2006) (4)
Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma. (2014) (4)
The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo (2008) (4)
Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial. (2008) (4)
A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models. (2008) (4)
Pharmacodynamic and Efficacy Studies of a Novel Proteasome Inhibitor NPI-0052 in Human Plasmacytoma Xenograft Mouse Model (2008) (4)
Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (2007) (4)
Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment (2017) (4)
The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia. (2006) (4)
An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma (2018) (4)
Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia (2014) (4)
Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104) (2018) (4)
Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide. (2007) (4)
Multiple myeloma: advances reported in 2013 are useful in the clinic. (2014) (4)
Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom’s Macroglobulinemia. (2007) (4)
Multiple myeloma (1994) (4)
The Treatment of Multiple Myeloma Patients Not Eligible for Asct (2010) (4)
Disentangling the Myeloma Web (2011) (4)
Cell-free DNA for the detection of emerging treatment failure in relapsed/refractory multiple myeloma (2021) (4)
Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial. (2004) (4)
Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma. (2006) (4)
Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM) (2008) (4)
AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (4)
Immunotherapy for multiple myeloma: insights from other models. (2002) (4)
Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom’s Macroglobulinemia. (2004) (4)
The Multiple Myeloma Research Foundation (MMRF) CoMMpassSM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes (2012) (4)
Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM) (2019) (4)
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias (2008) (4)
The PKC- Inhibitor Enzastaurin Inhibits MM Cell Growth, Survival and Migration in the Bone Marrow Microenvironment. (2005) (4)
NCCN practice guidelines for multiple myeloma (1998) (4)
A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies. (2014) (4)
A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma. (2017) (4)
Moving Toward Individualized Cancer Therapies (2008) (4)
Current trends: evolving concepts in transfusion medicine. Leukodepleted cellular blood components for prevention of transfusion-associated graft-versus-host disease. (1995) (4)
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation (2022) (4)
Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM). (2018) (4)
Inhibition of the TGF-beta signaling pathway in tumor cells. (2007) (4)
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. (2017) (4)
Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma. (2009) (4)
New agents and approaches in the treatment of multiple myeloma. (2003) (4)
Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia (2011) (4)
Phase 1, multicenter, open-label, dose-escalation, combination study (NCT02103335) of pomalidomide (POM), marizomib (MRZ, NPI-0052), and dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma (MM); study NPI-0052-107 preliminary results (2015) (4)
Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839 (2014) (4)
The current landscape of multiple myeloma treatment. (2008) (4)
A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma. (2005) (4)
Can thalidomide improve outcome in patients with multiple myeloma? (2006) (4)
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. (2012) (4)
The road to cure in multiple myeloma (2008) (4)
2-methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma (MM) cells. (2001) (4)
MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells (2019) (4)
Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study (2021) (4)
Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub (2020) (4)
A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstrom’s Macroglobulinemia. (2005) (4)
MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors (2010) (4)
Promotes Differentiation and Inhibits Apoptosis of JKB Acute Lymphoblastic Leukemia Cells (1997) (4)
XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma. (2009) (4)
Novel therapies for multiple myeloma. (2002) (4)
Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma (2016) (4)
Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide (2011) (4)
Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition (2015) (4)
ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004). (2012) (4)
The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment (2014) (4)
Targeted Overexpression of the Transcription Factor XBP-1 in B Cells Promotes Plasma Cell and Lymphoplasmacytic Neoplasms in Transgenic Mice. (2005) (4)
Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program (2010) (4)
Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma (2013) (3)
Avicins: A Novel Class of Anti-Myeloma Agents. (2004) (3)
The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells (2008) (3)
Potential alternatives to platelet transfusion (1994) (3)
Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom’s Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response. (2005) (3)
TAS-117, a Novel Selective Akt Inhibitor Demonstrates Significant Growth Inhibition in Multiple Myeloma Cells in Vitro and in Vivo (2012) (3)
Multiple myeloma: new uses for available agents, excitement for the future. (2015) (3)
Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma (2018) (3)
Combination of a Novel HDAC 6 Inhibitor ACY-241 with Anti-PD-L1 Antibody Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma (2016) (3)
Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma (2018) (3)
Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM. (2006) (3)
A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients. (2006) (3)
B protein of factor XIII: differentiation between free B and complexed B (1988) (3)
Recombinant growth factors. (1995) (3)
IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. (2013) (3)
Autologous and Allogeneic Transplantation for Multiple Myeloma (2004) (3)
Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma. (2009) (3)
Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma (2005) (3)
Don't Compromise Myeloma Care Due to COVID-19 Pandemic! (2020) (3)
Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma. (2007) (3)
Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma (2020) (3)
Functional dissection of inherited non-coding variation influencing multiple myeloma risk (2022) (3)
CD52 Is Expressed on Human Mast Cells and Is a Therapeutic Target for the Anti-CD52 Monoclonal Antibody Campath-1H in Waldenstrom’s Macroglobulinemia and Mast Cell Disorders. (2004) (3)
Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma. (2020) (3)
Dysregulated CD4 + CD25 + T- Regulatory Cells and TLRs in Myeloma. (2004) (3)
Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235. (2007) (3)
Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM) (2013) (3)
In vitro and in vivo activity of the VEGF receptor inhibitor PAZOPANIB (GW786034) in Multiple Myeloma: Therapeutic implications. (2006) (3)
Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in Myeloma in Vitro and In Vivo. (2009) (3)
Therapeutics , Targets , and Chemical Biology miR-30-5 p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt / b-Catenin / BCL 9 Pathway (2014) (3)
Transplantation with anti-B1 monoclonal antibody and complement treated autologous bone marrow for relapsed B-cell non-Hodgkin’s lymphoma (1985) (3)
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas (2011) (3)
The Rapid Evolution of Novel Therapies in Multiple Myeloma. (2016) (3)
Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression (2017) (3)
The future of treatment for patients with relapsed/refractory multiple myeloma. (2011) (3)
Bone Marrow Microenvironment Affects The Pathogenesis Of Multiple Myeloma Through Downregulation Of Alternative Splicing Factor Fox2 In Myeloma Cells (2013) (3)
Bispecific antibodies in multiple myeloma treatment: A journey in progress (2022) (3)
Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial. (2006) (3)
Cancer Therapy : Preclinical The Monoclonal Antibody nBT 062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD 138-Positive Multiple Myeloma Cells In vitro and In vivo (2009) (3)
Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (2015) (3)
HDAC 6 inhibitor WT 161 downregulates growth factor receptors in breast cancer (2017) (3)
Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells (2010) (3)
Specific Killing of Multiple Myeloma Cancer Cells by Epigallocatechin-3-Gallate Extracted from Green Tea. (2004) (3)
Analysis of Second Primary Malignancies (SPMs) in CALGB (Alliance)/ECOG/BMT CTN 100104 (2015) (3)
PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo. (2009) (3)
Serum Free Light Chain in Waldenstrom Macroglobulinemia. (2006) (3)
A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients (2016) (3)
SL-401, A Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance (2013) (3)
CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM) (2008) (3)
The MEK1/2 Inhibitor AZD6244 (ARRY-142886) Downregulates Constitutive and Adhesion-Induced c- MAF Oncogene Expression and Its Downstream Targets in Human Multiple Myeloma. (2006) (3)
A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma (2014) (3)
Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial. (2009) (3)
Proteasome Inhibitors as Therapy in Multiple Myeloma (2008) (3)
Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma. (2009) (3)
The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability (2015) (3)
Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma. (2007) (3)
RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia. (2009) (3)
Myeloma: Pathology, Diagnosis, and Treatment (2013) (3)
The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias. (2009) (3)
Mir-23b Plays a Critical Role As a Tumor Suppressor miRNA In Multiple Myeloma (2013) (3)
Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential (2018) (3)
Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma (2010) (3)
SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide (2014) (3)
Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results. (2007) (3)
Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials. (2012) (3)
Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma (2013) (3)
Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma (2011) (3)
Cancer Therapy : Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 against Multiple Myeloma Cells (2011) (3)
Preclinical evaluation of CD8+ Anti-BCMA mRNA CAR T-Cells for control of multiple myeloma (2019) (3)
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma (2006) (3)
Dendritic Cell Tumor Fusion Vaccination In Conjunction With Autologous Transplantation For Multiple Myeloma (2010) (3)
Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing (2013) (3)
Receptor activator of nuclear factor-kappa B (RANK) ligand expression: In human multiple myeloma cells. (2001) (3)
antitumor activity in multiple myeloma Small-molecule inhibition of proteasome and aggresome function induces synergistic (2005) (3)
Targeting IRE1α-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma (2010) (3)
Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions. (2007) (3)
The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom’s Macroglobulinemia. (2006) (3)
Function and expression of checkpoint inhibitors and immune agonists on immune cells in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and MM and tumor-specific T lymphocytes. (2017) (2)
Insights into the management of older patients with multiple myeloma. (2019) (2)
MYD88 L265P Promotes Survival of Waldenstrom's Macroglobulinemia Cells by Activation of Bruton's Tyrosine Kinase (2012) (2)
TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma. (2007) (2)
Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma. (2007) (2)
Novel hydroxamic acid-derived HDAC inhibitor LBH589 potently activates intrinsic and extrinsic apoptotic pathways, and induces tubulin hyperacetylation in multiple myeloma. (2005) (2)
The PI3K/Akt Pathway Is an Important Regulator of Homing and Adhesion in Waldenstrom’s Macroglobulinemia. (2006) (2)
Telomerase Inhibition, Telomere Shortening and Apoptotic Cell Death in Multiple Myeloma Cells Following Exposure to a Novel and Potent Telomerase Inhibitor (GRN163L), Targeting RNA component of Telomerase. (2004) (2)
Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. (1988) (2)
Effects of the indazolylpyrimidine GW786034 on angiogenesis and MM cell growth: Therapeutic implications. (2004) (2)
Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma (2018) (2)
SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma (2016) (2)
Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide (2014) (2)
Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401) (2021) (2)
Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. (2013) (2)
Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function (2017) (2)
Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells (2019) (2)
Pathophysiologic role of VEGF in hematologic malignancies (2007) (2)
Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo. (2009) (2)
Multiple myeloma. (2018) (2)
JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo. (2006) (2)
Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application. (2007) (2)
A multidimensional test of the attributional reformulation of learned helplessness (1984) (2)
New drugs for multiple myeloma. (2006) (2)
Mechanisms, biologic sequelae and clinical benefits of bortezomib-induced immunogenic cell death in multiple myeloma (2019) (2)
Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465. (2006) (2)
Treatment Patterns among Patients with Recently-Diagnosed Multiple Myeloma in a National Registry (2008) (2)
Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma (2013) (2)
What is High-Risk Myeloma? (2007) (2)
Microenvironment is a key determinant of immune checkpoint inhibitor response. (2022) (2)
Proteasome Stress Causes Apoptotic Sensitivity of Multiple Myeloma Cells to Proteasome Inhibition (2008) (2)
Abstract 5490: Non-overlapping promoter and super-enhancer-associated dependencies in multiple myeloma (2017) (2)
Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS) (2017) (2)
Therapeutic Discovery Adenosine A 2 A and Beta-2 Adrenergic Receptor Agonists : Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening (2012) (2)
Hematology: Setting the standard for newly diagnosed multiple myeloma (2011) (2)
Vascular Endothelial Growth Factor (VEGF) -induced migration of Multiple Myeloma cells is associated with ββββ 1-integrin- and PI3-kinase- dependent PKC αααα activation (2001) (2)
Overview of the AACR Clinical and Translational Cancer Research Think Tank Meeting (2012) (2)
Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma (2011) (2)
Targeting 19S-Proteasome Deubiquitinase Rpn11/POH1/PSMD14 in Multiple Myeloma (2015) (2)
Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia (2011) (2)
Inhibition of TGF-β Signaling in Multiple Myeloma and Its Bone Marrow Microenvironment (2008) (2)
Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial (2011) (2)
Proteomics-inspired precision medicine for treating and understanding multiple myeloma (2020) (2)
The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis (2018) (2)
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
Compartment-Specific Bioluminescence Imaging (CS-BLI): A High-Throughput Approach To Identify Novel Anti-Neoplastic Therapies That Overcome the Protection of Stromal Cells. (2007) (2)
Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. (2007) (2)
Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells. (2007) (2)
The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma (2016) (2)
Abstract 2645: Development of a first in class APRIL fully blocking antibody BION-1301 for the treatment of multiple myeloma (2017) (2)
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition. (2009) (2)
Investigational Agent MLN9708 Target Tumor Suppressor MicroRNA-33b in Multiple Myeloma Cells (2011) (2)
Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma. (2007) (2)
Abstract 3035: HDAC8 is recruited to DNA double strand breaks sites and affects the homologous recombination efficiency in multiple myeloma (2015) (2)
Bortezomib induces canonical nuclear factor- (cid:1) B activation in multiple myeloma cells (2009) (2)
Second-Generation Proteasome Inhibitors (2011) (2)
Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma (2014) (2)
Next Generation Sequencing in Multiple Myeloma (2015) (2)
The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM). (2007) (2)
AACR Cancer Progress Report 2015: Transforming Lives Through Precision Medicine (2015) (2)
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma (2000) (2)
Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside. (2007) (2)
Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition (2020) (2)
Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (2)
Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method (2014) (2)
Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003) (2013) (2)
CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis (2012) (2)
Human T and B cell derived malignancies. (1983) (2)
Mitochondria and caspase-independent cell-death triggered by GCS-100, a novel carbohydrate-based therapeutic in multiple myeloma (MM) cells. (2004) (2)
Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study (2019) (2)
Anti-Myeloma Activity of the Dual Akt/p70 S6K Inhibitor EXEL-6075. (2007) (2)
Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity (2021) (2)
Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenstrom Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment (2011) (2)
Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics (2008) (2)
Sequential CD34+ and CD4+ cell selection from leukapheresis components. (1998) (2)
Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma. (2009) (2)
Induction of Multiple Myeloma-Specific Cytotoxic T Lymphocytes Using HLA-A2.1-Specific CD19 and CD20 Peptides. (2004) (2)
Cells : Clinical Implications Antibody , Induces Cytotoxicity in Human Multiple Myeloma Mechanisms by which SGN-40 , a Humanized Anti-CD 40 (2004) (2)
Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 in Multiple Myeloma (2014) (2)
Differentially Expressed and Prognostically Significant Lincrnas May Impact Immune System and Tumor Progression in Multiple Myeloma (MM) (2015) (2)
Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells (2021) (2)
Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC (2017) (2)
Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. (2013) (2)
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. (2011) (2)
Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). (2015) (2)
Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). (2014) (2)
MLN-8237 (2010) (2)
Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma (2019) (2)
Combination of Anti-PD-L1 Antibody with IMiD® Immunomodulatory Drugs, HDAC Inhibitor ACY-1215, Bortezomib, or Toll-like Receptor 9 Agonist Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma (2015) (2)
Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability (2014) (2)
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment (2022) (2)
Vascular Endothelial Growth Factor (VEGF) Is a Growth and Survival Factor in Waldenstrom’s Macroglobulinemia. (2004) (2)
Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells (2019) (2)
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. (2022) (2)
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity (2010) (2)
GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: Two protocols (1991) (2)
Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM). (2007) (2)
Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma (2010) (2)
The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics. (2010) (2)
Who should receive leukodepleted blood components (1992) (2)
Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma. (2009) (2)
Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in Multiple Myeloma Patients over the Course of Treatment (2014) (2)
In vitro chemosensitivity of J-82 human bladder cancer cells (2004) (2)
Abnormal Expression of the Plasma Cell Differentiation Factor X-Box Protein 1 (Xbp-1) in Waldenstrom’s Macroglobulinemia. (2005) (2)
HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Dendritic Cells. (2009) (2)
INTERNATIONAL MYELOMA FOUNDATION IV Annual Robert A. Kyle Lifetime Achievement Award Dinner (2006) (2)
Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma. (2013) (2)
Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications (2020) (2)
Stem cell purging ex vivo. (1996) (2)
Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes (2022) (2)
PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo. (2005) (2)
Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study (2012) (2)
Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. (2011) (2)
Emerging treatments of multiple myeloma; beyond IMIDs and bortezomib (2009) (2)
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth. (2022) (2)
Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma (2014) (2)
Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma (2021) (2)
Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data. (2011) (2)
High-Throughput Microrna Profiling in Patients with Waldenstrom’s Macroglobulinemia. (2008) (2)
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma (2008) (2)
Redefining Mutational Profiling Using RNA-Seq: Insight into the Functional Mutational Landscape of Multiple Myeloma (2015) (2)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo. (2008) (2)
Human B Cell Populations Defined by the B1 and B2 Antigens (1986) (2)
CD27-mediated apoptosis is dependent on siva-induced caspase activation in human multiple myeloma (2005) (2)
Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society COVID-19 Dataset (2020) (1)
Alternative metrics for assessing clinical benefit with immunotherapy in oncology (2017) (1)
Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in IL-6- induced proliferation and survival of MM cells (2004) (1)
Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies (2022) (1)
LYMPHOID NEOPLASIA Pyk2 promotes tumor progression in multiple myeloma (2014) (1)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy (2000) (1)
Novel and potent telomerase antagonist (GRN163L) inhibits telomerase activity, resulting in telomere shortening and apoptosis of multiple myeloma cells (2005) (1)
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma (2022) (1)
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease (2014) (1)
Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1. (2023) (1)
Management Strategies for Relapsed Multiple Myeloma (2006) (1)
Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations (2009) (1)
A phase II study of dihydroxyanthracenedione (DHAD) (1982) (1)
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma (2022) (1)
Fusion Cell Vaccination In Conjunction With Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated With Responses In Patients With Multiple Myeloma (2008) (1)
The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma. (2006) (1)
Advances in Brief Functional Interaction between Retinoblastoma Protein and Stress-activated Protein Kinase in Multiple Myeloma Cells 1 (1999) (1)
Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw. (2006) (1)
Chapter 26 – Lymphoma/Myeloma (2008) (1)
Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM) (2015) (1)
Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13 (2019) (1)
Abstract C94: Deubiquitylases as novel anticancer targets: Discovery and development of novel USP7 inhibitors (2009) (1)
Compositions and methods for the treatment of neoplastic diseases (2005) (1)
A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism (2010) (1)
A First in Class APRIL Fully Blocking Antibody Targets Novel Immune Regulation of APRIL in Multiple Myeloma: Further Therapeutic Implication (2017) (1)
Inhibition Of H3K27-Methylome As a Novel Therapeutic Strategy In Multiple Myeloma (2013) (1)
A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism (2015) (1)
C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications (2008) (1)
Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability (2018) (1)
Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma (2015) (1)
Maximizing the clinical benefit of novel therapies in multiple myeloma. (2009) (1)
Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation (2010) (1)
NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors. (2004) (1)
Diagnostic Evaluation of t[4;14] in Multiple Myeloma. (2006) (1)
Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8+ cytotoxic T Lymphocytes Against Multiple Myeloma (2018) (1)
Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). (2009) (1)
Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application. (2009) (1)
Bone marrow biopsy in low-risk MGUS patients reveals a novel MGUS-like Smoldering multiple myeloma risk group (2019) (1)
Clinical Cancer Research: The 20th Anniversary (2015) (1)
CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFκB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma (2012) (1)
Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib (2008) (1)
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas (2022) (1)
TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application (2008) (1)
Constitutive expression of CD40L on bone marrow mast cells supports the growth of lymphoplasmacytic cells in patients with Waldenstrom's macroglobulinemia. (2004) (1)
Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone. (2005) (1)
Multiple myeloma. Preface. (2007) (1)
Updates to the NCCN Guidelines (2013) (1)
Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications. (2009) (1)
The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma (2012) (1)
Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma (2018) (1)
The research mission in myeloma (2009) (1)
Pomalidomide - An appraisal of its clinical development and role in the treatment of relapsed/refractory multiple myeloma (2015) (1)
Bion-1301: A Novel Fully Blocking APRIL Antibody for the Treatment of Multiple Myeloma (2016) (1)
Hospice Use Among Patients with Myeloma (2017) (1)
Abstract 3832: A proliferation-inducing ligand (APRIL) directly impacts immune regulatory subsets to regulate suppressive multiple myeloma bone marrow microenvironment (2018) (1)
Molecular Profiling of Extramedullary and Medullary Plasmacytomas. (2008) (1)
Regulation of Histone Deacetylase in Waldenström Macroglobulinemia (2008) (1)
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs (2022) (1)
1 JSK , a GST-activated nitric oxide generator , induces DNA double strand breaks , activates DNA damage response pathways , and induces apoptosis in vitro and in vivo in human multiple myeloma cells (2007) (1)
The Culture, Characterization and Triggering of B-Lymphocytes (2002) (1)
Blockade of Ubiquitin Receptor PSMD4/Rpn10 Triggers Cytotoxicity and Overcomes Bortezomib-Resistance in Multiple Myeloma (2018) (1)
A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients. (2007) (1)
Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity (2020) (1)
Translation of Targeted Therapies in Multiple Myeloma (2012) (1)
In vitro and in vivo proteasome activity profiles of bortezomib and a novel proteasome inhibitor NPI-0052 (2005) (1)
The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma (2013) (1)
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile. (2012) (1)
CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies (2010) (1)
Transfusion-associated graft-versus-host disease:Who is at Risk? (1991) (1)
Sensitivity of murine L1210 and human myeloma cells to chemotherapeutic agents assessed by in vivo chamber culture technique (1976) (1)
Recurrent Non-Coding Mutations in BCL7A May Have Significant Functional Consequence in Multiple Myeloma (2019) (1)
A Phase I, Multi-Dose, Dose Escalation Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma. (2004) (1)
The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM). (2011) (1)
Whole-genome bisulfite sequencing identifies HDAC3-mediated DNA methylation in multiple myeloma (2019) (1)
Targeting Multiple Myeloma Tumor Angiogenesis: Focus on VEGF (2013) (1)
A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action (2020) (1)
Polymorphisms In IRS1 and IL6R and Susceptibility To Multiple Myeloma (2013) (1)
Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma (2010) (1)
IGF-II is a major proliferative/anti-apoptotic cytokine and a therapeutic target in multiple myeloma, other hematologic neoplasias and solid tumors. (2004) (1)
Gamma heavy chain disease (2018) (1)
Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions. (2010) (1)
Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes (2011) (1)
A Combined Survival Model Integrating Gene Expression and Alternative Splicing Events Provides Higher Predicative Power for Risk Stratification (2010) (1)
The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM). (2005) (1)
Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo. (2004) (1)
Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models (2020) (1)
inhibition myeloma cells via mTORC 1 and extracellular signal-regulated kinase salvage pathway induces autophagy in multiple + Targeting NAD (2012) (1)
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (2018) (1)
MLN 120 B , a Novel I K BKinase B Inhibitor , Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (1)
of the International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: report (2012) (1)
Pancreas Cancer Molecular Targets for Therapy (2011) (1)
macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström (2014) (1)
The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication. (2006) (1)
Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma (2019) (1)
SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells (2010) (1)
Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex). (2005) (1)
Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor (2013) (1)
Stem cell transplant for first relapse from the multiple myeloma research foundation. (2006) (1)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma (2016) (1)
Advances in Biology and Therapy of Multiple Myeloma (2013) (1)
Genome Wide Transcriptomic Analysis Identifies Dysregulated Splicing Factor Profile with Molecular and Functional Role in Multiple Myeloma (2019) (1)
DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma (2011) (1)
Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Disease-Relevant Pathways and Overlaps with Common Cancer Biomarkers (2008) (1)
ESAs not the culprit : More studies required. Authors' reply (2008) (1)
Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00. (2006) (1)
Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma (2017) (1)
Inhibition Of Myeloid Derived Suppressor Cells (MDSC) In The Multiple Myeloma Bone Marrow Microenvironment (2013) (1)
Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma (2016) (1)
Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population (2013) (1)
polymerase chain reaction disorders using conventional and quantitative allele-specific monoclonal gammopathy, and other B-cell lymphoproliferative MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M (2013) (1)
Myeloma bone disease – pathogenesis of bone destruction and therapeutic strategies (2013) (1)
Graft-Versus-Host Disease (2001) (1)
PKC412 Effectively Inhibits Constitutively Activated FGFR3 Mutants in Murine Leukemia Models and t(4;14) Myeloma Cell Lines. (2004) (1)
Up-Front Management of Multiple Myeloma (2010) (1)
16p Deletion Involving BCMA Locus Is Frequent and Predominantly Observed with del17p (2021) (1)
ASH's Research Agenda Gets a Tune-Up (2017) (1)
Spontaneous DNA Damage and Aberrant Epigenome In Multiple Myeloma Constitute The Path To Disease Genomic Instability (2013) (1)
Immunomodulatory therapy improves outcome in multiple myeloma patients with clonal hematopoiesis (2019) (1)
Novel model to evaluate changes in gene expression profile of myeloma cells in vivo following interaction with human BM microenvironment. (2005) (1)
Suppression Of Uninvolved Immunoglobulin Has Significant Clinical Implication Including Predicting Relapse In Multiple Myeloma (2013) (1)
Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism. (2009) (1)
Abstract 2530: Antimyeloma activity of a small molecule multi-targeted kinase inhibitor, AT9283, via potent aurora kinase and STAT3 inhibition (2010) (1)
Extended 5‐Year Follow‐Up of the Phase 3 ELOQUENT‐2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM): MM‐271 (2018) (1)
Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma (2021) (1)
Novel heteroclitic XBP1 peptides evoking antigen-specific cytotoxic T lymphocytes targeting various solid tumors. (2013) (1)
Biological correlates to support a clinical role for tagraxofusp, a novel targeted therapy directed to CD123, in combination with pomalidomide and dexamethasone, to target plasmacytoid dendritic cells in poor-risk patients with multiple myeloma. (2020) (1)
The clinical potential of proteasome inhibition (2004) (1)
Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle (2010) (1)
A Novel Alkylating Agent Melphalan Flufenamide Ethyl Ester Induces an Irreversible DNA Damage in Multiple Myeloma Cells (2014) (1)
Retrospective Analysis of Thrombocytopenia in Relapsed Multiple Myeloma Patients (2011) (1)
Vaccination with DC/tumor fusion cells results in cellular and humoral anti-tumor immune responses in patients with multiple myeloma DC/myeloma fusion vaccine induces immune responses (2017) (1)
Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma (2014) (1)
Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies. (2004) (1)
Strategies to overcome barriers to accrual (BtA) to NCI-sponsored clinical trials: A project of the NCI-Myeloma Steering Committee Accrual Working Group (NCI-MYSC AWG). (2013) (1)
Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy (2013) (1)
Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy (2010) (1)
XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells (2015) (1)
Allotransplantation for multiple myeloma. (2001) (1)
The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies. (2009) (1)
The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable (2003) (1)
High Resolution Genome-Wide Analyses Revealed That Bortezomib Selects a Prediagnosis Clone In Relapsed Patients with Multiple Myeloma (2010) (1)
The monoclonal antibody nBT 062 conjugated to maytansinoids has potent and selective cytotoxicity against CD 138 positive multiple myeloma cells in vitro and in vivo (2008) (1)
Killing of Drug-Sensitive and Resistant Myeloma Cells and Disruption of Their Bone Marrow Stromal Interaction by HuLuc63, a Novel Humanized Anti-CS1 Monoclonal Antibody. (2006) (1)
Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib) (2006) (1)
APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma (2019) (1)
The Evolution and Maintenance of the Multiple Myeloma Cell Clone within the Liquid Bone Marrow Compartment: Therapeutic Implications (2010) (1)
Pharmacogenomics Study of Biological Pathways Related to Bortezomib Activity in Myeloma. (2007) (1)
Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease. (2014) (1)
Cytokines and Signal Transduction in Multiple Myeloma (2013) (1)
Constitutive B-Cell Maturation Antigen (BCMA) Activation In Human Multiple Myeloma Cells Promotes Myeloma Cell Growth and Survival In The Bone Marrow Microenvironment Via Upregulated MCL-1 and NFκB Signaling (2013) (1)
Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease. (2007) (1)
Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment (2008) (1)
HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma (2016) (1)
JAK-STAT3 Pathway Regulates CD38 Expression on Multiple Myeloma Cells (2018) (1)
Serotonin Receptor Antagonists Have an In Vitro and In Vivo Anti-Myeloma Effect That Is Mainly Mediated by Caspase Dependent Apoptosis. (2006) (1)
A 3D‐Bioprinted Multiple Myeloma Model (Adv. Healthcare Mater. 7/2022) (2022) (1)
Abstract 2634: Polymorphisms in DNA repair genes and risk of multiple myeloma (2012) (1)
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. (2021) (1)
Initial Treatment of Multiple Myeloma in Transplant-Eligible Patients (2010) (1)
A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal Antibody Targets Multiple Myeloma Cells in the Bone Marrow Microenvironment (2014) (1)
Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response (2021) (1)
HDAC8 Mediates Homologous Recombination and Cytoskeleton Integrity in Myeloma with Potential Impact on Cell Growth and Survival (2014) (1)
Targeting Cell-Death Pathways in Multiple Myeloma: Therapeutic Implications (2005) (1)
Assessing proteasome workload to predict response and overcome resistance to proteasome inhibitors in multiple myeloma (2007) (1)
Abstract B100: Development of fargeted multiple myeloma cancer vaccine and antigen-specific T-cell immunotherapy using novel Immunogenic-engineered heteroclitic BCMA peptides (2019) (1)
A Fully Human Antagonist Anti-CD40 Antibody Triggers Significant Antitumor Activity Against Human Multiple Myeloma. (2004) (1)
APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma (2018) (1)
Phenotypic and Functional Effects of Novel Akt Inhibitor Perifosine on Immune System. (2008) (1)
Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern (2016) (1)
Targeting Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma (2018) (1)
Vaccination with DC/Multiple Myeloma Fusions in Conjunction with Stem Cell Transplantation. (2007) (1)
Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma (2019) (1)
Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052. (2005) (1)
Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology (2021) (1)
Introduction: New approaches to the treatment of multiple myeloma (2001) (1)
Dysfunctional T Regulatory Cells in Myeloma: Molecular Mechanisms of Dysregulation. (2005) (1)
To transplant or not to transplant (2005) (1)
Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma (2014) (1)
PRMT5 inhibitors on the (myeloma) road (2018) (1)
The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM). (2006) (1)
Abnormalities of Platelets and Platelet Support (2003) (1)
Intracellular NAD + Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity (2012) (1)
Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma. (2004) (1)
Proteasome Inhibitor Does Not Affect the Function of Human Immune Systems: Effects on Dendritic Cells, T Lymphocytes and NK Cells. (2005) (1)
DAPK2 and PIM1 Are Myeloma-Associated Antigens That Elicit Coordinated B and T Cell Immunity After Syngeneic HSCT. (2009) (1)
Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells (2012) (1)
Vision Statement for Multiple Myeloma: Future Directions. (2016) (1)
Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia. (2006) (1)
Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients (2020) (1)
Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs) (2014) (1)
High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients. (2007) (1)
The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma (2013) (1)
Bortezomib Targets Multiple Myeloma Endothelial Cells. (2004) (1)
PtdIns 3-kinase (2011) (1)
Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia (2015) (1)
Expression Profile Signature to Predict Response to Bortezomib and Dexamethasone Combination Therapy in Newly-Diagnosed Myeloma: Moving towards Prospective Prediction (2008) (1)
A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications (2016) (1)
R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma. (2005) (1)
In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple Myeloma. (2005) (1)
Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment (2012) (1)
Targeting Sp1 Transactivation In Waldenstrom's Macroglobulinemia: a Novel Therapeutic Option (2010) (1)
Reversine: A Chemical Probe Providing Insight into Myeloma Biology and Potential Therapeutic Applications. (2006) (1)
MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu. (2009) (1)
What Can CCR Do for You? (2010) (1)
Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia (2006) (1)
Myeloma: Principles of pathway directed therapy (2013) (1)
JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells. (2005) (1)
Synthetic Lethal Approaches to Exploit Replicative Stress in Aggressive Myeloma (2014) (0)
KDM5A reinforces MYC transcriptional program and promotes myeloma cell growth (2019) (0)
Combination Proteasome Inhibitor Therapy (2008) (0)
Chapter 2 Resistance to Proteasome Inhibitors in Multiple Myeloma (2017) (0)
Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma (2011) (0)
Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy (2019) (0)
Role of Allotransplantation in Myeloma (2010) (0)
Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia (2019) (0)
Abnormalities of Red Cells and Red Cell Support (2003) (0)
Abstract 5352: Genome-wide CRISPR-cas9 screening identifies KDM6A as a modulator of CD38 expression in multiple myeloma: Therapeutic implications (2022) (0)
In Myeloma, the Prognostic Impact of Hyperdiploidy Is Mainly Related to the Gain of Chromosome 5 (2008) (0)
Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma (2021) (0)
Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients (2022) (0)
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia (2022) (0)
Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma (2019) (0)
Alternate Splicing Factor Fox2 Affects Growth and Survival of Multiple Myeloma Cells (2011) (0)
Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma (2007) (0)
Alpha heavy chain disease (2018) (0)
A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1 (2013) (0)
therapeutic option in multiple myeloma is a promising α Blockade of XBP1 splicing by inhibition of IRE1 (2013) (0)
Cooperative impact of Utx loss and Braf V600E mutation induces myeloma in mice (2019) (0)
The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma (2008) (0)
Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma (2008) (0)
Canonical and Non Canonical Activation of Hedgehog Pathway in Multiple Myeloma (2008) (0)
Gene Expression Profile Alone Is Inadequate In Predicting Complete Responses In Multiple Myeloma (2010) (0)
Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity (2021) (0)
A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2021) (0)
Hepatitis C Viral Infection Is Not Associated with Waldenstrom’s Macroglobulinemia. (2005) (0)
Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma. (2009) (0)
BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics (2014) (0)
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis (2014) (0)
Delineating Molecular Mechanisms of Proteasome and Histone Deacetylase Inhibitor-Induced Myeloma Cytotoxicity (2012) (0)
Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution (2013) (0)
American S ociety o f C linical O ncology C linical P ractice Guidelines: T he R ole o f B isphosphonates i n Multiple M yeloma (2002) (0)
Oncogenomics to target myeloma cells in the bone marrow microenvironment (2008) (0)
Functional and Clinical Impact of Splicing Factor Dysregulation in Multiple Myeloma (2015) (0)
LYMPHOID NEOPLASIA MYD 88-independent growth and survival effects of Sp 1 transactivation in Waldenström macroglobulinemia (2014) (0)
Myeloma Bone Marrow Stromal Cells Detection of Kaposi's Sarcoma Herpesvirus DNA Sequences in Multiple (2013) (0)
The BCL9 Oncogene Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic and Angiogenic Properties to Myeloma Cells (2008) (0)
Molecular Mechanisms Underlying the Development of Drug Resistance in Multiple Myeloma. (2004) (0)
Inhibition of human plasmacytoma cell growth by a novel JAK kinase inhibitor. (2004) (0)
Abstract IA13: Novel therapeutic targets in multiple myeloma (2018) (0)
A Tribute to Jan Gosta Waldenströ (1997) (0)
Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications (2018) (0)
Evaluation of the Ras/B-Raf/SHP-2 Axis in B Cell Malignancies. (2004) (0)
Proteasome inhibition as an anticancer target (2005) (0)
Novel Mechanisms Underlying IMiDs Resistance in Multiple Myeloma: Therapeutic Implications (2017) (0)
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma (2023) (0)
Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans (2019) (0)
JNCI role of interleukin 16 in Multiple Myeloma Pathogenesis : a Potential Novel therapeutic target ? (2012) (0)
Blood Cancer Discovery Turns One. (2021) (0)
Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma (2008) (0)
Abstract 2074: ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma (2022) (0)
Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma (2014) (0)
Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. (2005) (0)
Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma (2021) (0)
Reply to M. Roschewski et al. (2014) (0)
Novel therapeutic targets in multiple myeloma. (2015) (0)
Hsp90 Is Critical for the Regulation of Phenotype and Functionality of Human Dendritic Cells. (2005) (0)
The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma (2020) (0)
Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma (2016) (0)
Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1). (2019) (0)
Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma (2021) (0)
CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin. (2009) (0)
Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors. (2004) (0)
Cancer Therapy: Preclinical A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma (2009) (0)
Autologous blood transfusion computer software program (1995) (0)
Plasmacytoma (Solitary bone plasmacytoma, extramedullary plasmacytoma) (2019) (0)
receptor associated with antibody response to BCMA, a plasma-cell membrane Graft-versus-tumor response in patients with multiple myeloma is (2013) (0)
Splicing fator SRSF1 is dsregulated in Multiple Myeloma With Functional and Clinical Significance (2017) (0)
Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Bone Marrow and Peripheral Blood Dendritic Cells From Patients With (2008) (0)
P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS (2015) (0)
The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for Risk Stratification of Multiple Myeloma (MM) (2017) (0)
Targeting Proteasome- Associated Ubiquitin Receptor PSMD4/Rpn10 in Multiple Myeloma (2017) (0)
Targeting Deubiquitylating Enzyme USP1 in Multiple Myeloma (2015) (0)
Abstract 2004: Phenotypic and molecular characterization of inter- and intraclonal heterogeneity in multiple myeloma and Waldenstrom macroglobulinemia (2015) (0)
Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and drug resistance. (2013) (0)
Activity of Human T Lymphocytes and NK Regulation of Phenotype and Functional Heat Shock Protein 90 Is Critical for (2017) (0)
Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide (2015) (0)
Scientific section designations: Lymphoid Neoplasia Title: p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma Short title: TP53RK is a novel therapeutic target in myeloma (2016) (0)
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma (2019) (0)
B in Waldenstrom macroglobulinemia κ Targeting NF (2013) (0)
Transfusion Medicine (1996) (0)
Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma (2010) (0)
Halofuginone, an Old Anticoccidosis Drug, Induces Apoptosisin Multiple Myeloma Cells, Associated with Down Regulation of MCL1. (2007) (0)
Abstract 400: Establishment and characterization of a novel IL6-dependent HLA-A2+ human myeloma cell line LNT1 (2010) (0)
macroglobulinemia The Akt pathway regulates survival and homing in Waldenstrom (2008) (0)
Identiﬁcation of novel antigens with induced immune response in monoclonal gammopathy of undetermined signiﬁcance (2009) (0)
The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma (2019) (0)
Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM) (2011) (0)
Enhanced cytotoxicity of monoclonal antibody SGN-40 and immunomodulatory drug IMiD3 against human multiple myeloma (2004) (0)
PI3-kinase- dependent PKCα activation (2001) (0)
Transfusion-Related Infectious Diseases (Table 149-6) (2003) (0)
Moving Toward Personalized Therapies in Myeloma (2009) (0)
Long Noncoding RNA RROL Provides Chromatin Scaffold for MYC-WDR82 Interaction to Impact Lipid Metabolism and Tumor Cell Growth in Multiple Myeloma (2021) (0)
Genomic Evolution of Multiple Myeloma In Vivo over Time. (2006) (0)
Identification of Target Antigens Recognized in MGUS for Immunotherapeutic Approaches. (2005) (0)
Clinical Impact of an Internet-Based Tool to Provide Expert Guidance for Multiple Myeloma (MM) from 2012 to 2014 (2014) (0)
Altered Expression of Epigenetic Modifiers Identifies Novel Biomarkers and Therapeutic Targets in AL Amyloidosis (2021) (0)
The Added Value of 18-F FDG PET/CT in Defining Prognosis and Response in Myeloma (2012) (0)
Procedes et compositions de traitement du cancer au moyen d'inhibiteurs de la proteasome (2003) (0)
Sequencing the Myeloma Genome (2011) (0)
Mcl-1 Fragment Mcl-1(128–350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity (2008) (0)
Activity of Plk Inhibitor BI2536 on Myeloma Cells (2008) (0)
An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012. (2013) (0)
synergistic activity in multiple myeloma Combination of the mTOR inhibitor rapamycin and CC-5013 has (2013) (0)
Triona Ni Chonghaile Response to Cytotoxic Chemotherapy Pretreatment Mitochondrial Priming Correlates with Clinical (2011) (0)
Treatment of solid tumors (2006) (0)
Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications (2021) (0)
Lack of Mcl-1 Confers Resistance to Bortezomid in Multiple Myeloma. (2004) (0)
Reply to the Letter to the Editor from Noopur Raje and Kenneth C. Anderson (2008) (0)
multiple myeloma cell lines CD40 activation mediates p53-dependent cell cycle regulation in human (2008) (0)
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma (2019) (0)
TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation (2019) (0)
Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1. (2007) (0)
Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity (2019) (0)
CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma (2022) (0)
Incorporating Novel Agents into Upfront Myeloma Therapy (2008) (0)
Immunotherapeutic Strategies for Multiple Myeloma (2020) (0)
Inhibition of c-Myc Expression and Function in Hematologic Malignancies (2011) (0)
Clinical Anti-Myeloma Activity of Aminobisphosphonates (2011) (0)
Looking Forward: An Update to the CCR Instructions for Authors (2014) (0)
Abstract B09: Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma. (2015) (0)
Gene Transcriptional Activity Analysis in the 6q Region in Waldenstrom Macroglobulinemia (WM) Using ChIP-on-Chip Technology (2008) (0)
Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma (2019) (0)
Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity. (2007) (0)
Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells (2010) (0)
Targeting Ubiquitin Receptor Rpn13/ADRM1 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity (2019) (0)
in Waldenström macroglobulinemia MYD88-independent growth and survival effects of Sp1 transactivation (2014) (0)
Changing the Paradigm. (2020) (0)
Mir-222-221 Induce Dexamethasone Resistance by Targeting BBC3/PUMA in Human Multiple Myeloma (2011) (0)
Physical and Functional Association of the MRN Complex with Human Telomerase in Multiple Myeloma. (2006) (0)
Abstract LB110: Multiple myeloma cells depend on the NRF1-DDI2 proteasome stress response pathway for survival (2021) (0)
Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy (2022) (0)
Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): Examining whether different variables govern different time segments of survival. (2009) (0)
associated with adverse patient outcome The sumoylation pathway is dysregulated in multiple myeloma and is (2014) (0)
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting (2018) (0)
Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors. (2007) (0)
Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma. (2010) (0)
GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Growth in Vivo (2008) (0)
myeloma MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple (2012) (0)
The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 Targets Myeloma Cells and Their Bone Marrow Microenvironment. (2007) (0)
Attitudes toward Participation in Research, New Treatments, and Medication Side Effects among Multiple Myeloma and Myelodysplastic Syndrome Patients - The Patient Registries at Slone: Myeloma & MDS. (2007) (0)
Biology and Therapeutic Targeting of Sp1 Transactivation In Myeloma (2010) (0)
In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM). (2004) (0)
Abstract LB217: ROBO1 promotes homing, dissemination, and survival of multiple myeloma within the bone marrow microenvironment (2021) (0)
REVIEW ARTICLE The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Multiple Myeloma: An Evidence-Based Review (2003) (0)
Abnormalities of White Cells and White Cell Support (2003) (0)
P-134: Quality of life, psychological distress, and prognostic awareness in caregivers of patients with Multiple Myeloma (2021) (0)
BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma. (2006) (0)
In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis (2022) (0)
Multiple myeloma. (2000) (0)
Abstract PR05: A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans (2020) (0)
autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the (2012) (0)
Perceptions of prognosis in caregivers of multiple myeloma (MM) patients. (2021) (0)
PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment (2022) (0)
Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. (2006) (0)
Primary Cancer Site (2011) (0)
Cytokines in Multiple Myeloma (2007) (0)
Multiple myeloma clinical practice guidelines in oncoloqy. (2004) (0)
Preclinical Development Molecular and Cellular Effects of NEDD 8-Activating Enzyme Inhibition in Myeloma (2012) (0)
Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature (2020) (0)
241 Targeting the myeloma cell in its bone marrow microenvironment (2004) (0)
Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical Outcome in Multiple Myeloma (2014) (0)
Table 136-3, Classification of Monoclonal Gammopathies (2003) (0)
Sp1 Transcription Factor as a Novel Therapeutic Target in Multiple Myeloma (MM) (2008) (0)
T1153 PI 3-Kinase Inhibitor (Wortmannin) Inhibits DNA Recombination, Genomic Instability, and Growth of Barrett's Adenocarcinoma Cells (2010) (0)
SAR650984 (SAR) directly induces multiple myeloma (MM) cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by Pomalidomide (2015) (0)
Upregulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma and other malignancies (2007) (0)
Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma (2021) (0)
associated with antibody responses to highly expressed antigens Complete response to donor lymphocyte infusion in multiple myeloma is (2013) (0)
Targeting therapy for resistant multiple myeloma with a novel inhibitor of NF-KB, NPI-1387. (2005) (0)
Evaluation of the Specificity and Cytotoxicity of Three Proteasome Inhibitors. (2005) (0)
Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo (2015) (0)
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy (2019) (0)
PF600 IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS (2019) (0)
Biology and Prognostic Implications of Bone Marrow Plasmacytoid Dendritic Cells in Multiple Myeloma Pathogenesis By Single-Cell RNA Sequencing (2022) (0)
NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells. (2009) (0)
JNK activation and Fas up-regulation precede proteasomal degradation of topoisomerase I in SN38-mediated cytotoxicity against multiple myeloma. (2004) (0)
well tolerated in patients with relapsed multiple myeloma Immunomodulatory drug CC-5013 overcomes drug resistance and is (2013) (0)
How is Bortezomib Best Used in Myeloma (2011) (0)
Preparation and clinical utility of leukocyte-reduced platelets. (1994) (0)
Biological pathways and in vivo anti-tumor activity induced by atiprimod in multiple myeloma (MM). (2006) (0)
Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub (2021) (0)
Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma (2021) (0)
Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential (2013) (0)
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma (2016) (0)
Biologic impact of proteasome inhibition in MM cells - from the aspects of preclinical studies (2012) (0)
Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma (2010) (0)
Aberrant RHAMM (receptor for hyaluronan-mediated motility) splicing in MM is associated with upregulation of PTBP1/2 (polypyrimidine tract binding protein 1/2): therapeutic implications (2019) (0)
Insulin-like growth factor-1 receptor (IGF-1R/CD221): A target for monoclonal antibody-based therapy to overcome drug-resistance in multiple myeloma (MM), other hematologic malignancies and solid tumors (2004) (0)
OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma (2021) (0)
Myeloma Microenvironment Controls T Regulatory Cell Activity: Potential Target for Therapeutic Interventions. (2006) (0)
Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells. (2005) (0)
Induction Combination Novel Agent Therapies in Myeloma (2011) (0)
P-150: Quality of life, psychological distress, and prognostic awareness in patients with Multiple Myeloma (2021) (0)
microenvironment migration of multiple myeloma cells in the bone marrow GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and (2013) (0)
Abstract B58: Decreasing the time to activate clinical trials: Initial data from the Multiple Myeloma Research Consortium (MMRC) model (2009) (0)
Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells. (2006) (0)
The Biological Sequelae of Stromal Cell-derived Factor-1 (cid:1) in Multiple Myeloma 1 (2002) (0)
Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM) (2020) (0)
A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts (2020) (0)
Abstract 1734: Drug- induced generation of Mcl-1128-350fragment triggers apoptosis in multiple myeloma cells through upregulation of c-Jun. (2013) (0)
The International Myeloma Society comes of age. (2012) (0)
Neoplastic Diseases of the Blood (1996) (0)
Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma (2022) (0)
1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma (2019) (0)
DNA repair processes target transcribed region in multiple myeloma (2018) (0)
Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells. (2009) (0)
Functional and Clinical Relevance of Splicing Factor SRSF1 in Multiple Myeloma (MM) (2014) (0)
Identification of Novel Antigens with Induced Immune Response in MGUS. (2006) (0)
polymerase chain reaction disorders using conventional and quantitative allele-specific monoclonal gammopathy , and other B-cell lymphoproliferative MYD 88 L 265 P in Waldenström macroglobulinemia , immunoglobulin (2013) (0)
Pomalidomide for the treatment of relapsed and refractory multiple myeloma (2014) (0)
Defining the differentiation states of multiple myeloma at single cell resolution – Identifying opportunities for immunotherapy (2019) (0)
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics (2023) (0)
Inhibition of Ubiquitin Receptor PSMD4/Rpn10 as Therapeutic Strategy to Overcomes Bortezomib-Resistance in Multiple Myeloma cells (2019) (0)
The chronological order of copy number changes in hyperdiploid multiple myeloma patients (2018) (0)
Abstract 3283: APRIL/BCMA activation promotes human multiple myeloma progression and further induces immunosuppressive bone marrow microenvironment (2016) (0)
factors Response patterns of purified myeloma cells to hematopoietic growth (2011) (0)
relapsed, refractory multiple myeloma Clinical factors predictive of outcome with bortezomib in patients with (2013) (0)
Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications. (2007) (0)
Role Of Sirtuin-6 In Maintenance Of Genomic Instability In Multiple Myeloma Cells (2013) (0)
Apurinic/Apyrimidinic Endonuclease 1 Induced Genomic Instability Causes T-Cell Acute Lymphoblastic Leukemia in Zebrafish (2015) (0)
Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM) (2015) (0)
Comprar Bortezomib in the Treatment of Multiple Myeloma | Ghobrial, Irene M. | 9783764389475 | Springer (2011) (0)
Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability (2021) (0)
Evolving Treatment Patterns of Healthcare Providers (HCPs) and Multiple Myeloma (MM) Experts from 2013-2017: Analysis of an Annually Updated Online Treatment Decision Tool (2017) (0)
Genomic Analysis of Endothelial Progenitor Cells In Multiple Myeloma Reveals Aberrant Gene Pathways Common to Tumor Cells (2010) (0)
synergistic cytotoxicity in multiple myeloma vivo in Combination of proteasome inhibitors bortezomib and NPI-0052 trigger (2012) (0)
PKC412, a Small Molecule Tyrosine Kinase Inhibitor, Regulates Survival and Proliferation Pathways in Waldenström Macroglobulinemia (2008) (0)
Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology (2014) (0)
Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition (2020) (0)
Blood Cancer Discovery Turns One. (2021) (0)
Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications. (2007) (0)
OAB-022: Monoallelic deletion of BCMA locus is a frequent feature in MM and is associated with increased genomic loss (2021) (0)
26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma (2022) (0)
RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma (2020) (0)
Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising anti‐MM activity of AS703569 demonstrated in preclinical studies in vitro and in vivo (2009) (0)
The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction (2013) (0)
Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population. (2010) (0)
Targeting Multiple RTKs in Cancer (2008) (0)
Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells. (2006) (0)
Predicting Response to Proteasome Inhibitor Therapy (2009) (0)
Internal Medicine: Waldenstrom's Macroglobulinemia to Wilson's Disease (2007) (0)
Identification Of Novel Alternative Splice Variants Of Sirtuins In Multiple Myeloma: Therapeutic Implications (2013) (0)
Development of B-cell maturation antigen (BCMA)-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma. (2022) (0)
Targets in multiple myeloma and other disorders (2013) (0)
Perifosine Affects Phenotype and Function of Human Myeloid Dendritic Cells (2010) (0)
A novel panel of protein biomarkers for predicting response to thalidomide‐based therapy in newly diagnosed multiple myeloma patients (2011) (0)
Mimicking Myeloma Niche Ex Vivo (2014) (0)
Guideline to Multiple Myeloma Treatment Strategies (2012) (0)
A Proliferation Inducing Ligand (APRIL) Directly Impacts Immune Regulatory Subsets to Regulate Suppressive Multiple Myeloma Bone Marrow Microenvironment (2017) (0)
Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches (2019) (0)
Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs (2008) (0)
Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma (2015) (0)
(LY317615.HCl) novel, orally available small-molecule inhibitor enzastaurin Targeting PKC in multiple myeloma: in vitro and in vivo effects of the (2013) (0)
Perturbation of Genomic Instability by Wortmannin in Myeloma. (2009) (0)
Lymphoblastic Leukemia Cells Promotes Differentiation and Inhibits Apoptosis of JKB AcuteINK 4 Ap (1997) (0)
Whole Exome Sequencing Of Multiple Myeloma Reveals An Heterogeneous Clonal Architecture and Genomic Evolution (2013) (0)
Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma. (2007) (0)
Systemic Light Chain Amyloidosis - Panel Members (2014) (0)
A Novel Real-Time In Vivo Homing Model of Multiple Myeloma. (2006) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Abstract 660: Inhibition of centrosomal clustering suppresses tumor growthin vivo (2011) (0)
Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma (2012) (0)
YWHAE/14-3-3ε expression impacts the proteasome load contributing to proteasome inhibitor sensitivity in multiple myeloma (2019) (0)
cells in the multiple myeloma microenvironment in humans Tumor-promoting immune-suppressive myeloid-derived suppressor (2013) (0)
1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma (2018) (0)
MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation. (2006) (0)
Selecting Patients Most Likely to Respond to Therapy (2008) (0)
Variation in the Treatment of Multiple Myeloma in the Real World (2020) (0)
Ubiquitin Receptor PSMD4/Rpn10 Is a Novel Therapeutic Target in Myeloma (2021) (0)
Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics (2011) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Targeting the Ubiquitin-proteasome system for the Treatment of Multiple Myeloma and Other Human Diseases (2010) (0)
Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma. (2006) (0)
Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma (2004) (0)
Clinical use of leukocyte-poor platelets from a new Apheresis System (1990) (0)
The JAK inhibitor INCB20 induces antiproliferative and apoptotic effects in human myeloma cells in vitro and in vivo (2005) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy (2019) (0)
Abstract 5719: Long intergenic non-coding RNAs: a new independent risk predictors in multiple myeloma (2017) (0)
Verfahren und zusammensetzungen zur krebsbehandlung unter verwendung von proteasom-hemmern (2003) (0)
An Integrative Analysis of Network Motifs and Gene Expression Data to Discover Experimentally Testable Transcription Factor-miRNA-Gene Regulatory Loops In Multiple Myeloma (2010) (0)
Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients (2017) (0)
Combined Histone Deacetylase and Proteasome Inhibitor Therapy in Myeloma (2012) (0)
Abstract A21: Inhibition of USP7 for the treatment of multiple myeloma and other malignancies. (2015) (0)
Plasmacytoid Dendritic Cells in Myeloma (2010) (0)
Integrating Gene and Mir Expression Profiles and Regulatory Network Structures to Define Aberrent Feed Forward Loops with Functional and Clinical Implications in Myeloma. (2012) (0)
Multiple myeloma (2001) (0)
Characterization of TFDP1 As Novel Regulatory Gene in Multiple Myeloma (2012) (0)
Familial Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, and Other Cancers (2009) (0)
Inhibition of Kynurenine-3-Monooxygenase in Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Myeloma Immunity (2019) (0)
30 – Multiple Myeloma (2015) (0)
Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma (2021) (0)
First, once a certain regimen becomes the standard of care, this implies that an alternative approach by definition is an inferior thera- peuticoption.Webelievethatthestandardofcareinthetreatmentof patientswithnewlydiagnosedMMistoattemptattainingaremission inpreparationforstemcelltransplant(SCT)prov (2006) (0)
An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway (2010) (0)
In vitro generation of highly purified functional invariant NKT cells in multiple myeloma: A strategy for immunotherapy. (2006) (0)
therapeutic applications B blockade in multiple myeloma: κ - Biologic sequelae of nuclear factor (2013) (0)
Novel Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders, (2011) (0)
Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents (2012) (0)
Abstract PR04: Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma. (2015) (0)
Traitement de troubles lies a la degradation de proteines (2006) (0)
A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells (2011) (0)
myeloma interaction of tumor and bone marrow accessory cells in multiple Immunomodulatory effects of lenalidomide and pomalidomide on (2012) (0)
A Panel of POTENTIAL PROTEIN BIOMARKERS for Predicting CLINICAL RESPONSE to Thalidomide IN Newly Diagnosed MULTIPLE MYELOMA PATIENTS. (2009) (0)
Elevated Nuclease Activity Correlates With Clinical Spectrum Of Plasma Cell Dyscrasias (2013) (0)
RNA-Seq De Novo Assembly of Clonal Immunoglobulin Rearrangements Identifies Interesting Biology and Uncovers Prognostic Features in Multiple Myeloma (2016) (0)
The Effect of Insulin-Like Growth Factor 1 on Waldenstrom Macroglobulinemia (2008) (0)
PF593 THE IMPACT OF RESPONSE KINETICS FOLLOWING INITIAL THERAPY FOR MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS (2019) (0)
181: Identification of Graft-Versus-Myeloma Target Antigens following Syngeneic Hematopoietic Stem Cell Transplantation (2008) (0)
Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia (2008) (0)
Optimizing Mechanisms for Induction of Immunogenic Cell Death to Improve Patient Outcome in Multiple Myeloma (2018) (0)
The Pathophysiologic Role of the Bone Marrow Environment and its Niches in Multiple Myeloma (2010) (0)
Germinal Center-Derived Lymphomas and Plasmacytomas in Mice with Targeted Deletion of MiR-15a/16-1 in Activated B Cells (2016) (0)
Resveratrol Exerts AntiproliferativeActivity and Induces Apoptosis inWaldenstro« m’s Macroglobulinemia (2008) (0)
A Novel Inosine Monophosphate Dehydrogenase Inhibitor VX-944 Overcomes Conventional Drug-Resistance in Multiple Mueloma Cells in the Bone Marrow Microenvironment. (2004) (0)
Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes Are Enhanced By HDAC6 Inhibitor ACY241 (2016) (0)
stromal cells mediated interactions with bone marrow - tumorigenicity via c-maf CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and (2013) (0)
Title: Disentangling the myeloma web (2011) (0)
High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma (2019) (0)
The Hypoxia-Selective Epigenetic Agent, Rrx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells (2015) (0)
Multiple Myeloma Cells MDM2 Protein Overexpression Promotes Proliferation and Survival of (2008) (0)
inhibitor PS-341 Molecular mechanisms mediating antimyeloma activity of proteasome (2013) (0)
The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing (2016) (0)
The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma (2008) (0)
Phenotypic and Functional Effects of Novel HDAC Inhibitor LBH589 On Human Lymphocyte Populations. (2009) (0)
patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in (2012) (0)
Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma. (2009) (0)
Gene Mutations Detected by Whole-Exome Sequencing and Recurrent Cytogenetic Abnormalities Are Independent Events in Multiple Myeloma (2011) (0)
From the guest editor: the evolving treatment paradigm in multiple myeloma. (2009) (0)
Roundabout 1 (ROBO1)/SLIT2 Is a Novel Signaling Pathway in Multiple Myeloma Promoting Survival and Bone Marrow Niche Interaction (2016) (0)
Transfusion medicine: Editorial overview (1995) (0)
T1154 Role of Homologous Recombination in Telomere Maintenance and Evidence of ALT Pathway in Barrett's Adenocarcinoma Cells (2010) (0)
Lenalidomide Maintenance Therapy in Multiple Myeloma (2012) (0)
VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis. (2004) (0)
Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome (2019) (0)
Clonal Heterogeneity and Immune Tumor Microenvironment in Waldenström Macroglobulinemia (2019) (0)
The CureCloud Research Initiative, a Next-Gen Direct-To-Patient Clinico-Immuno-Genomic Registry (2019) (0)
RFP2 Knockdown Disrupts Cell Growth and Induces Apoptosis in Multiple Myeloma (2008) (0)
Genetic Susceptibility Markers of Multiple Myeloma in African-Americans (2014) (0)
Checkpoint expression on immune cells in the patients with multiple myeloma or pre-malignant diseases: Therapeutic Implication for Combination Immu (2019) (0)
Deubiquitylating Enzyme USP1 As Therapeutic Target in Multiple Myeloma (2016) (0)
Areas of Consensus and Differences Among a Panel of Experts on the Optimal Use of Newly Approved Agents to Treat Multiple Myeloma (MM): Results from an Annually Updated Online Decision Support Tool (2016) (0)
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling (2023) (0)
The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma (2008) (0)
Prediction of Thalidomide Response in the Newly Diagnosed Untreated Multiple Myeloma Patients Based on a Panel of Protein Biomarkers (2008) (0)
CCR1 Inhibition Targets Osteoclast-Myeloma Adhesion and Exerts in Vivo Anti-Osteoclast Activity (2008) (0)
APRIL/B Cell Maturation Antigen (BCMA) Signaling Cascades Promote Human Multiple Myeloma Growth and Mediate Immunosuppression in the Bone Marrow Microenvironment Via IL-10, TGF-b, and PD-L1 (2015) (0)
Identification and validation of HLA-A24 XBP1, CD138, and CS1 peptides and induction of antigensspecific CD8+ T cell immunity using a multipeptide cocktail: Preclinical basis for vaccine therapy in HLA-A24 patients with multiple myeloma and other cancers (2017) (0)
Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma (2019) (0)
CD40 Ligand Stimulation of Multiple Myeloma Cells Results in Upregulation of Surface Expressed Heat Shock Proteins and Increased Antigenicity. (2004) (0)
Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia (2014) (0)
e- Blood Compartment-speciﬁc bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function (2012) (0)
Identification of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma (2018) (0)
Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM) (2014) (0)
Chapter 76 – Multiple Myeloma and Other Plasma Cell Neoplasms (2012) (0)
Staying Vigilant on Health Care Reform (2017) (0)
MicroRNA Signature in Waldenstrom Macroglobulinemia (2008) (0)
Whole Genome Sequencing Defines the Clonal Architecture and Genomic Evolution in Myeloma: Tumor Heterogeneity with Continued Acquisition of New Mutational Change (2011) (0)
Continued Progress in Treatment Options for Multiple Myeloma: From Past to Present and Future (2007) (0)
Phase 1/2 dose-escalation study of marizomib (MRZ, NPI-0052) plus low dose dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma; study NPI-0052-101 (NCT00461045) (2015) (0)
Abstract IA27: New insights into therapeutic targets in multiple myeloma. (2015) (0)
Gene Addiction in Myeloma (2008) (0)
Standing Up for Patients (2017) (0)
Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway. (2006) (0)
Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma (2020) (0)
Introducing The Clinical Connection (2007) (0)
Other Plasma Cell Dyscrasias (2003) (0)
Cancer Therapy : Preclinical Dual Inhibition of Canonical and Noncanonical NFk B Pathways Demonstrates Signi fi cant Antitumor Activities in Multiple Myeloma (2012) (0)
Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells (2018) (0)
Treatment Outcomes With Pomalidomide in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma and del(17p13) and/or t(4p16/14q32) Cytogenetic Abnormalities Who Have Received Prior Therapy With Lenalidomide and Bortezomib (2012) (0)
Epigenetic modulation by VidazaTM induces apoptosis and overcomes in vitro drug resistance in human multiple myeloma cells. (2007) (0)
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma (2008) (0)
Corrigendum to <'Novel therapeutic strategies for multiple myeloma'> <[Experimental Hematology 2015; 43: 732-741]>. (2021) (0)
Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma (2013) (0)
Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma (2015) (0)
MLN120B, a Novel IKBKinase B Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (0)
and inhibits immune function in multiple myeloma Elevated IL-17 produced by Th 17 cells promotes myeloma cell growth (2010) (0)
Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma (2021) (0)
Multiple Myeloma Cells Express IL-17A Creating An Autocrine Loop: An Attractive Therapeutic Target (2013) (0)
Bcl-B and Nur77/TR3: a deadly combination (2007) (0)
Abstract 394: A novel anti-a proliferation-inducing ligand hAPRIL.01A monoclonal antibody targets multiple myeloma cells in the bone marrow microenvironment (2015) (0)
CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells. (2006) (0)
igh-dose Therapy with Single Autologous ransplantation versus Chemotherapy for Newly iagnosed Multiple Myeloma : A Systematic Review nd Meta-analysis of Randomized Controlled Trials (2007) (0)
Abstract 567: The lysosomal transporter SLC46A3 is a potential predictive biomarker for antibody-drug conjugates bearing the non-cleavable warheads SG3376 and DM1 (2018) (0)
A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma (2020) (0)
US Cooperative Group Trials (2009) (0)
Abstract 644: Novel anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity via enhanced effector function and direct tumor cell killing (2014) (0)
Other Therapeutic Modalities (2003) (0)
Motivation for Education (2017) (0)
Effects of Tanespimycin On Glucocorticoid Receptor Translocation. (2009) (0)
Alkylphosphocholine Perifosine Inhibits Myeloma Cell Growth While Inducing Myeloid Hyperplasia in a Murine Myeloma Model. (2005) (0)
A Step Toward Safer Immunomodulatory Drugs (2010) (0)
Genomic patterns of progression in smoldering multiple myeloma (2018) (0)
Primary Waldesntrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease. (2009) (0)
Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study (2015) (0)
Hsp90 Is Critical for the Regulation of Human T Lymphocytes and NK Cell Phenotype and Function. (2005) (0)
Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions (2008) (0)
Abstract #1393: MicroRNA in the biology, prognosis and therapy of Waldenstrom macroglobulinemia (2009) (0)
A First In-Depth Analysis of Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications (2019) (0)
Abstract 642: TRAF2 mediates sensitivity to immunomodulatory drugs via NF-κB and ERK signaling in myeloma cells (2020) (0)
Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma (2019) (0)
38 INTIVED Bortezomib therapy of multiple myeloma (2008) (0)
APOBEC3B is induced by activation of DNA damage pathway and regulates the survival and treatment response in human multiple myeloma (2019) (0)
Development of Novel CD138 Antigen-Specific Peptide Capable of Eliciting Myeloma-Specific Cytotoxic T Lymphocytes Response. (2005) (0)
LYMPHOID NEOPLASIA MUC1-C drives MYC in multiple myeloma (2016) (0)
Cancer Therapy : Preclinical In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent , Melphalan-Flufenamide , against Multiple Myeloma Cells (2013) (0)
Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma. (2007) (0)
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia. (2009) (0)
CDK4/6 Inhibition Suppresses Myeloma Cell Growth and Viability via Perturbation of E2F Proliferative Program (2019) (0)
Modulation of heparanase expression in myeloma tumor cell lines by defibrotide: A novel mechanism of anti-tumor activity (2007) (0)
The Multiple Myeloma Research Consortium Genomics Initiative. (2007) (0)
Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function (2010) (0)
Therapeutic Potential of Targeting the Immunoproteasome (2009) (0)
Abstract LB193: Lysine demethylase 5A is required for MYC driven transcription in multiple myeloma (2021) (0)
High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment (2019) (0)
report of the International Myeloma Workshop Consensus Panel 2 Consensus recommendations for risk stratification in multiple myeloma (2011) (0)
in vivo synergistic cytotoxicity in multiple myeloma Combination of proteasome inhibitors bortezomib and NPI-0052 trigger (2008) (0)
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma (2023) (0)
Fighting Cancer Gets Personal (2010) (0)
inhibiting STAT3 Nifuroxazide inhibits survival of multiple myeloma cells by directly (2013) (0)
Correction: Heat Shock Protein 90 Is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells (2013) (0)
Erratum (2006) (0)
Roundabout 1 (ROBO1) Mediates Multiple Myeloma Survival and Interaction with the Bone Marrow Microenvironment (2019) (0)
Comprar Multiple Myelomas, An Issue of Hematology / Oncology Clinics | Kenneth C. Anderson | 9781416050827 | Saunders (2007) (0)
Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma (2014) (0)
Activation of B-Cell Maturation Antigen (BCMA) on Human Multiple Myeloma Cells by a Proliferation-Inducing Ligand (APRIL) Promotes Myeloma Cell Function in the Bone Marrow Microenvironment. (2007) (0)
Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma (2021) (0)
Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma (2019) (0)
Sp1 Inhibition Affects Cell Growth and Survival In Waldenstrom’s Macroglobulinemia Through a MYD88-Independent Pathway (2013) (0)
Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches (2014) (0)
Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma (2022) (0)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (E1A11): a multicenter, open label, phase 3, randomized, controlled trial (2020) (0)
Monoclonal Antibody–Based Therapies in Human Multiple Myeloma (2009) (0)
Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications (2018) (0)
Myeloma Heterogeneity within Its Complex Immune Ecosystem (2019) (0)
NFκB Signaling and Mcl-1 Are Critical in B Cell Maturation Antigen-Promoted Multiple Myeloma Cell Growth and Survival (2014) (0)
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma (2019) (0)
Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk (2022) (0)
The novel, orally available small- molecule PKC inhibitor enzastaurin (LY317615.HCl) in multiple myeloma: in vitro and in vivo effects and therapeutic implications (2007) (0)
Modulation of Gene Expression Profile and In Vivo Anti-Myeloma Activity Induced by Valproic Acid, a Histone Deacytylase Inhibitor. (2007) (0)
Abstract 2894: Novel heteroclitic XBP1 peptides induce antigen-specific memory CD3+CD8+ T cells expressing critical T cell markers and transcription regulators (2014) (0)
sensitivity to therapy cells with the bone marrow microenvironment and enhances their CXCR 4 inhibitor AMD 3100 disrupts the interaction of multiple myeloma (2009) (0)
The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo. (2007) (0)
Sydney E. Salmon (2000) (0)
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N-Deacetyl-N -(3-Mercapto-1-Oxopropyl)-Maytansine against CD56 Multiple Myeloma Cells (2004) (0)
Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM). (2004) (0)
F18-Fluorodeoxyglucose PET Scanning in Multiple Myeloma (2009) (0)
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. (2023) (0)
A new model of plasma cell proliferation (2004) (0)
Blood Cancer Discovery Turns One. (2021) (0)
Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1 (2010) (0)
Proteomic Analysis of Multiple Myeloma Identifies Upregulation of CRIK Protein, a Novel Protein Regulating Migration and Adhesion (2008) (0)
Oral Proteasome Inhibitors in Multiple Myeloma (2012) (0)
Microenvironment-Induced Genomic Instability in Multiple Myeloma (2012) (0)
Growth characteristics of cyclophosphamide sensitive and resistant mouse lpc-1 plasmacytoma cell lines in in vitro diffusion chambers. Abstr. (1980) (0)
Multiple Myeloma: To T or Not to T, What Will the Answer Be? (2011) (0)
Effects of Transfusion on the Immune System (2003) (0)
Beyond Business As Usual (2017) (0)
Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma. (2009) (0)
Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib. (2004) (0)
Use of Alkylating Agents Among Patients with Multiple Myeloma in a National Registry, 2006-2008. (2009) (0)
Niches Within the Multiple Myeloma Bone Marrow Microenvironment (2007) (0)
A Green Tea Polyphenol, Epigallocatechin-3-Gallate, Induces Selective Apoptosis in Multiple Myeloma Cells: Mechanism of Action and Therapeutic Potential. (2005) (0)
Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation. (2007) (0)
Mu-heavy chain disease (2018) (0)
Profiling patient response to marizomib therapy (2010) (0)
Deficient double strand breaks repair of bone marrow plasma cells correlates with better clinical outcome of multiple myeloma patients (2014) (0)
Non-overlapping Promoter and Super-enhancer Driven Processes Support Myeloma Cell Growth and Survival via Distinct Regulatory Axes (2017) (0)
Way to Make a Statement: Government Policy and ASH (2017) (0)
Predictors of high yield and purify of CD34(+) cell-selected PBPC, collected from patients with multiple myeloma. (1999) (0)
In Vivo Imaging Model of Multiple Myeloma and Its Cellular Interaction with the Bone Marrow Microenvironment (2008) (0)
marrow milieu Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone (2013) (0)
The Genomic Landscape of Multiple Myeloma Complex Structural Variations (2017) (0)
Methods for treating multiple myeloma using combination therapies based anti-CS1 (2007) (0)
Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Overlaps with Myeloma Tumor Cells and Common Cancer Gene-Pathways. (2007) (0)
Abstract 972: B-cell maturation antigen (BCMA) activation in human multiple myeloma cells promotes myeloma cell growth and survival in the bone marrow microenvironment via upregulated MCL-1 and NFκB signaling (2014) (0)
Novel Therapy for Relapsed Myeloma (2008) (0)
Association of tagging SNPs in genes related to IGF-1 or IL-6 signaling with risk of multiple myeloma : selected findings (2008) (0)
P-020: Altered mRNA splicing identifies novel biomarkers and therapeutic targets in AL (Amyloid light-chain) Amyloidosis (2021) (0)
Therapeutics , Targets , and Chemical Biology GF-15 , a Novel Inhibitor of Centrosomal Clustering , Suppresses Tumor Cell Growth In Vitro and In Vivo (2012) (0)
Abstract 6347: Immunotherapeutic application of induced pluripotent stem cell technology: Rejuvenated BCMA-specific CD8+T cells for multiple myeloma (2022) (0)
8 Things Rheumatologists Should Know About Heavy Chain Disease (2014) (0)
bortezomib- containing regimens cell collection following initial therapy with thalidomide, lenalidomide or Mobilization in myeloma revisited: IMWG consensus perspectives on stem (2009) (0)
Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing (2011) (0)
Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2 (2014) (0)
Evolution of Genomic Changes and Their Significance in Myeloma. (2009) (0)
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance (2009) (0)
Cancer Therapy: Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells (2011) (0)
Targeting Protein Homeostasis in Novel Therapeutics (2007) (0)
Aplidine for treatment of multiple myeloma (2004) (0)
56: Vaccination with DC/MM Fusions in Conjunction with Stem Cell Transplantation (2008) (0)
Chromosomal deletions and amplifications in multiple myeloma detected by 500K single nucleotide polymorphism array analysis. (2005) (0)
specific cytotoxic T lymphocytes - Ex vivo induction of multiple myeloma (2013) (0)
in First Complete Remission CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia (2013) (0)
Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM). (2008) (0)
High-throughput oncogene mutation detection in human cancers by mass spectrometry-based genotyping (2006) (0)
Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers (2016) (0)
OFD1-Mediated T Cell Responses in MGUS Patients: Implications for Immunotherapy. (2007) (0)
16(4A Expression in Multiple Myeloma and Plasma Cell Leukemia (1997) (0)
Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment. (2007) (0)
ß-Catenin Is a Novel Marker of the Aggresome and Suggests Disruption of the Proteasome-Aggresome-Autophagasome Pathway in Multiple Myeloma In Vivo. (2006) (0)
Abstract 1978: The poly-SUMO protein specific E3 ubiquitin ligase RNF4 is induced in multiple myeloma and reduces bortezomib-induced cell killing (2010) (0)
Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13 (2020) (0)
P-099: Perturbation of CDK7 and super-enhancer driven transcriptional programs synergistically halts multiple myeloma cell proliferation (2021) (0)
Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy (2021) (0)
The management of infection in myeloma (2013) (0)
Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance (2019) (0)
Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma (2019) (0)
Immmunomodulatory Drug (Revamid) Co-stimulates T cells via The B7-CD28 pathway (2003) (0)
Profiling proteasome activity in multiple myeloma and lymphoma (2004) (0)
A Small Molecule-induced Targeted Degradation of Ubiquitin Receptor Rpn13 as a Novel Therapeutic Strategy in Multiple Myeloma (2019) (0)
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma (2020) (0)
Developing Faithful Models to Evaluate Novel Therapeutics (2009) (0)
LYMPHOID NEOPLASIA A clinically relevant in vivo zebra ﬁ sh model of human multiple myeloma to study preclinical therapeutic ef ﬁ cacy (2016) (0)
Small Molecule Therapeutics Delineating themTORKinasePathwayUsingaDual TORC 1 / 2 Inhibitor , AZD 8055 , in Multiple Myeloma (2014) (0)
PDC-E2, a Common Auto Antigen in Primary Biliary Cirrhosis (PBC) Is Also a Target of an Antibody Response in Patients Who Achieve Complete Remission after Donor Lymphocyte Infusion. (2004) (0)
Current trends: evolving concepts in transfusion medicine: potential alternatives to platelet transfusion. (1994) (0)
Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma (2020) (0)
Novel Proteasome Inhibitor Therapy (2007) (0)
Future Directions in Blood Component Therapy (2003) (0)
TAS-116. Second-generation HSP90-alpha/beta inhibitor, Cancer therapy (2018) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
A Novel Murine Model for Human Waldenstrom’s Macroglobulinemia. (2004) (0)
TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment (2020) (0)
Genomic Landscape and Its Prognostic Implications in Multiple Myeloma Using a Targeted Sequencing Approach (2015) (0)
Causes of Pancytopenia (2003) (0)
Abstract A82: Prognostic relevance and genomic profile of circulating tumor cells in multiple myeloma (2015) (0)
The Unfolded Protein Response Is a Determinant of Disease Actvity in Waldenstrom’s Macroglobulinemia (WM). (2005) (0)
The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy (2015) (0)
Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition (2008) (0)
Defining Fundamental B Cell-Subset Dysfunction in Myeloma (2016) (0)
Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma (2012) (0)
Multiple myeloma gammopathies A high-risk , Double-Hit , group of newly diagnosed myeloma identi fi ed by genomic analysis (2018) (0)
BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells (2022) (0)
Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma (2018) (0)
Mono clonal antibodies against surface antigens of a drug resistant bladder cancer cell line (1983) (0)
A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas (2021) (0)
Functional and Molecular Impact Of Dp1-Dependent Alternate Splicing In Multiple Myeloma (2013) (0)
Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications (2018) (0)
Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells. (2006) (0)
A CME / CE-accredited activity RECENT ADVANCES IN THE TREATMENT OF MULTIPLE MYELOMA Proceedings From a Post-IMW Roundtable (2011) (0)
In Vivo Effects of Zoledronic Acid on Bone Remodeling. (2007) (0)
Novel Mouse Models of Human Myeloma (2007) (0)
Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment. (2004) (0)
The novel proteasome inhibitor BzLLL-COCHO is a specific inhibitor of proteasome activity (2005) (0)
[4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth In vitro and in vivo activity of atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro (2005) (0)
Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma (2019) (0)
P881: CDK7 CONTRIBUTES TO METABOLIC REPROGRAMMING IN MM CELLS THROUGH C-MYC MEDIATED TRANSCRIPTIONAL CONTROL OF GLYCOLYTIC GENES (2022) (0)
Deciphering the chronology of copy number alterations in Multiple Myeloma (2018) (0)
Comprar Multiple Myeloma | Kenneth C. Anderson | 9781420045109 | Informa Healthcare (2007) (0)
Abstract 2142: The nuclear export protein CRM1 (XPO1) regulates multiple myeloma cell growth, osteoclastogenesis, and myeloma-induced osteolysis. (2013) (0)
Circulating tumor DNA in the peripheral blood as early predictor of clinical outcome in relapsed/ refractory multiple myeloma (2019) (0)
The Tyrosine Kinase Src Regulates Adhesion and Survival in Waldenström Macroglobulinemia (2008) (0)
In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway. (2007) (0)
In Vitro Anti-Myeloma Activity of the Multitargeted Kinase Inhibitor Midostaurin in the Context of Heterotypic Cocultures of Myeloma Cells with Nonmalignant Microenvironmental Accessory Cells (2011) (0)
S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM (2019) (0)
SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma. (2004) (0)
antitumor activity in Waldenström macroglobulinemia Protein kinase C inhibitor enzastaurin induces in vitro and in vivo (2008) (0)
GRN163L, a Novel and Potent Telomerase Inhibitor, Inhibits Myeloma Cell Growth In Vitro and In Vivo . (2005) (0)
Abstract 638: Lenalidomide treatment enhances the anti-tumor activities of XBP1 specific cytotoxic T lymphocytes by increasing the frequency and tumor-specific response of central memory CD3+CD8+ T cells (2014) (0)
Title: Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients (2013) (0)
MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM) (2021) (0)
Development of PRPK Directed Phthalimides (2021) (0)
Phenotypic and Functional Effects of Perifosine on Dendritic Cells. (2007) (0)
Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8+ cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders (2018) (0)
Phase 3 FIRST Trial in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Patients From Canada and the United States (2019) (0)
Immunomodulatory Effects of Lenalidomide and Bortezomib on Bone Marrow Stroma Cell and CD4 T Cell Interaction in Multiple Myeloma. (2008) (0)
Abstract 2934: Targeting Bruton's tyrosine kinase with PCI-32765 blocks growth and survival of multiple myeloma and Waldenström macroglobulinemia via potent inhibition of osteoclastogenesis, cytokines/chemokine secretion, and myeloma stem-like cells in the bone marrow microenvironment (2012) (0)
CCR New Strategies New Strategies in the Treatment of Multiple Myeloma (2013) (0)
The Functional Role of Microrna 15a/16-1 as Tumor Suppressor Genes in Multiple Myeloma. (2009) (0)
1 Targeting NF-κ B in Waldenstrom Macroglobulinemia (2008) (0)
Compositions for treating cancer using the proteasome inhibitor PS-341 (2003) (0)
B279 Panel of Potential Proteomic Biomarkers for Predicting Response to Thalidomide in Multiple Myeloma (2009) (0)
IL-17A-Mediated Notch Signaling in Multiple Myeloma (2014) (0)
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer (2021) (0)
XBP-1 a Selective and Specific Target for Immunotherapy in Myeloma. (2005) (0)
Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma (2022) (0)
A Clinically Relevant Zebrafish in Vivo Model of Human Multiple Myeloma (MM) to Study Disease Biology and Preclinical Therapeutic Efficacy (2012) (0)
Population Candidate Gene Association Study (2011) (0)
RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma (2011) (0)
Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications (2010) (0)
(1165) Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation. Session Type: Poster Session, Board #319-I (2007) (0)
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence (2011) (0)
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. (2021) (0)
High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib. (2007) (0)
Critical Role of Split Hand/Foot Malformation Type 1 (SHFM1) in Homologous Recombination and Cell Survival in Multiple Myeloma (MM) (2015) (0)
Indirubin-3’-Monoxime Acts as a Novel Proteasome Inhibitor: Therapeutic Application in Multiple Myeloma (2021) (0)
The Polycomb Group Transcriptional Repressor Bmi-1 Is Constitutively Expressed in Multiple Myeloma (MM) Cells and Modulates Proliferation through a Mechanism Independent of the Ink4a/ARF Locus. (2004) (0)
Acquisition of New In Vivo Genomic Change over Time in Multiple Myeloma. (2007) (0)
Time to Development of Treatment-Emergent Extramedullary and Osseous Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib (2014) (0)
In Vitro Generation of Highly-Purified Functional Invariant NKT Cells: A Strategy for Immunotherapy in Multiple Myeloma. (2005) (0)
Targeting Replicative Stress to Treat Hematological Disorders (2015) (0)
Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application (2019) (0)
Gauging Progress in a Decades-Old Fight (2012) (0)
Abstract 288: Targeting Sp1 transactivation in Waldenstrom's macroglobulinemia: A novel therapeutic option (2012) (0)
Lymphoblastic Leukemia Cells Promotes Differentiation and Inhibits Apoptosis of JKB Acute INK4A p16 (2008) (0)
Stem Cell Transplantation in Multiple (2008) (0)
p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma (2016) (0)
Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells (2014) (0)
Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery. (2009) (0)
apoptosis myeloma by induction of caspase-dependent and -independent Honokiol overcomes conventional drug resistance in human multiple (2010) (0)
Dendritic Cell/Multiple Myeloma (MM) Fusion Vaccine with Lenalidomide Maintenance after Autologous Hematopoietic Cell Transplant (HCT) Induces MM-Specific Immunity, BMT CTN 1401 (2022) (0)
Defining a Murine Model To Study Bone Disease in Multiple Myeloma (MM). (2006) (0)
P-093: Ubiquitin receptor PSMD4/Rpn10 as therapeutic target in Multiple Myeloma (2021) (0)
Molecular Pathways Induced by Tumor–Microenvironment Interactions in Myeloma and the Regulatory Role of Heat-Shock Proteins (2009) (0)
Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma (2022) (0)
Debate - Change Therapy for High/Low Risk Patients - No (2015) (0)
Can We Treat Myeloma at Early Stages (2011) (0)
Timing the initiation of multiple myeloma (2020) (0)
Interpretation klinischer Studiendaten zum Multiplen Myelom: Übertragung der Ergebnisse auf die klinische Praxis (2019) (0)
Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma (2022) (0)
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors (2022) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
The Genomic and Transcriptional Landscape of Waldenström’s Macroglobulinemia Impacts Disease Presentation, Overall Survival, and Therapeutic Response (2015) (0)
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13 (2021) (0)
CHALLENGES IN THE MANAGEMENT OF HIGH-RISK MULTIPLE MYELOMA (2023) (0)
Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation. (2005) (0)
Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation (2022) (0)
Novel Multiple Myeloma Treatments and Agents in Development (2013) (0)
CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma (2022) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma (2023) (0)
Shock Protein 90 Inhibition on Dendritic Cell Phenotypic and Functional Effects of Heat (2007) (0)
Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma (2022) (0)
Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success (2015) (0)
Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma (2023) (0)
Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression (2022) (0)
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant (2020) (0)
Expressed fusion gene landscape and its impact in multiple myeloma (2017) (0)
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. (2023) (0)
PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (2019) (0)
Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma. (2007) (0)
miR-26a as a novel potential therapeutic via inhibit CD38 translation and may overcome datatumumab resistance in multiple myeloma(MM) (2020) (0)
1 MOLECULAR PREDICTORS OF CLINICAL RESPONSE TO THE PROTEASOME INHIBITOR BORTEZOMIB: CLINICAL IMPLICATIONS FOR INDIVIDUALIZED PATIENT-SPECIFIC ANTI-CANCER THERAPEUTIC ALGORITHMS (2005) (0)
Abstract 4629: Multiple myeloma susceptibility loci examined in African and European ancestry populations (2015) (0)
Waldenström macroglobulinemia lymphoplasmacytic cells by activation of Bruton tyrosine kinase in A mutation in MYD88 (L265P) supports the survival of (2014) (0)
The proteasome and proteasome inhibitors in multiple myeloma (2017) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia (2022) (0)
High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma. (2023) (0)
Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML) (2018) (0)
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
Modulation of Signaling Cascades by Inhibitors of Histone Deacetylase and Akt (2009) (0)
A Pandemic Preparedness Network for Individuals Living with Compromised Immune Systems. (2023) (0)
LYMPHOID NEOPLASIA APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment (2016) (0)
Modulation of NK, T, & B cell sub-populations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma. (2019) (0)
against CD138+ multiple myeloma cells DM1 - Cytotoxic activity of the maytansinoid immunoconjugate B-B4 (2013) (0)
Transfusion medicine. (1994) (0)
Clinical genetics laboratories use divergent demographic frameworks across countries: comparing data structures for race, ethnicity, and ancestry on test requisition forms (2021) (0)
High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler) (2013) (0)
A chimeric humanized anti-CD40 antibody renders human multiple myeloma (MM) cells refractory to the mitogenic and protective effects of IL-6 (2003) (0)
Pathway-Catenin / BCL 9 β Therapeutic Tool by Targeting the Oncogenic Wnt / miR-30-5 p Functions as a Tumor Suppressor and Novel (2014) (0)
17 – Multiple Myeloma and Plasma Cell Dyscrasias (2010) (0)
Antitumor activity of the maytansinoid immunoconjugate B-B4 (B-B4-DM1) against CD138+multiple myeloma cells. (2003) (0)
Universally Observed Loss of BCL7A Allows Activation of IRF4 and Its Transcriptional Activity in Multiple Myeloma Cells (2021) (0)
Novel murine model to study modulation of genes and molecular pathways induced following in vivo interaction between multiple myeloma cells and human BM milieu. (2006) (0)
Direct Assessment of Proteasomal Degradation as a Potential Predictor of Responsiveness to Bortezomib in Multiple Myeloma (2006) (0)
migration and homing in multiple myeloma dependent - Mechanisms of regulation of CXCR4/SDF-1 (CXCL12) (2013) (0)
Biologic Sequelae of CDC2 Inhibition in MM. (2007) (0)
The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells. (2004) (0)
University of Southern Denmark Rational design of a trimeric April-based CAR-binding domain enables efficient targeting of multiple myeloma Schmidts, (2019) (0)
Abstract 383: APOBEC3B is induced by activation of DNA repair pathway and modulates the survival and treatment response in human multiple myeloma (2019) (0)
Identification of Novel Myeloma-specific Peptides Able to Generate Specific and Effective Cytotoxic T Lymphocytes: Potential Therapeutic Application in Multiple Myeloma (2005) (0)
S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST? (2019) (0)
172: Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions (2008) (0)
RFP2 Modulates 20S Proteasome Activity, NF Kappa B Activation, and Tumor Cell Growth in Multiple Myeloma. (2009) (0)
p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma. (2006) (0)
Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules. (2005) (0)
Proteasome inhibition regulates survival and homing in Waldenstrom Macroglobulinemia (WM) (2008) (0)
A Phase 3 Randomized, Open-label Study of Isatuximab (SAR650984) Plus Pomalidomide (POM) and Dexamethasone (DEX) Versus POM and DEX in RRMM (2017) (0)
The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche (2019) (0)
Local Mate Competition Experimental Evolution of Reduced Sex Ratio Adjustment Under (2011) (0)
Alternatives to blood products (1995) (0)
Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro, and Inhibits Tumor Growth and Improves Survival in in Vivo Multiple Myeloma(MM) Animal Models (2008) (0)
The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis (2018) (0)
Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index (2011) (0)
Oncoprotein 18 (Op18) : A Differentially Expressed Gene Is a Novel Therapeutic Target in Multiple Myeloma (2008) (0)
Clonotypic Bone Marrow-Derived Endothelial Progenitor Cells in Multiple Myeloma. (2006) (0)
Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study (2019) (0)
Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM). (2005) (0)
The myeloma bone marrow environment and survival signaling (2013) (0)
Dysregulated Apurinic/Apyrimidinic Endonucleases (Ape1 and Ape2) Lead to Genetic Instability in Multiple Myeloma. (2004) (0)
New Therapeutic Strategies in Multiple Myeloma (2012) (0)
Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu (2021) (0)
NovelTherapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau PhaseMultiple Myeloma (2007) (0)
Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues. (2004) (0)
Compromised Nuclear Sirtuins Activity Sensitizes BRCA-Proficient multiple Myeloma Cells to DNA Damage Agents (2012) (0)
Proteasome activity is cell-type dependent. (2003) (0)
Abstract PR13: p53-related protein kinase is a novel prognostic marker and therapeutic target in multiple myeloma (2017) (0)
Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway. (2010) (0)
Molecular Pathophysiology of Myeloma and Clinical Applications: Abstract: MM‐011 (2017) (0)
Abstract 141: Targeting protein secretion as a novel therapeutic strategy in AL amyloidosis (2022) (0)
Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma (2012) (0)
High dose of Zoledronic acid inhibits both osteoclasts and osteoblasts in an In Vivo mouse model (2008) (0)
Induction of T Cell Immunity Using a Multipeptide Cocktail Containing XBP1, CD138 and CS1 Peptides in Smoldering Multiple Myeloma (2012) (0)
Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance (2011) (0)
The Evolving Role of Autologous Stem Cell Transplantation in the Treatment of Multiple Myeloma (2010) (0)
Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells. (2009) (0)
OAB-009: Genome-wide CRISPR interference screen identifies RNA Regulator of Lipogenesis (RROL) as a leading LncRNA dependency in Multiple Myeloma (2021) (0)
Promise and Obstacles to Gene Expression Profiling in Multicenter Trials (2007) (0)
Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom’s Macroglobulinemia, the Role of the ERK and PKC Pathways. (2006) (0)
A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. (2009) (0)
PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE-CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA (2019) (0)
A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (2018) (0)
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma (2022) (0)
Effect of Thalidomide and Revlimid on the Gene Expression That Reveals Molecular Circuitries Involved in T Cell Co-Activation. (2004) (0)
Multiple Myeloma - Coping with a Disrupted Immune Environment (2015) (0)
The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development (2011) (0)

This paper list is powered by the following services:

Other Resources About Kenneth C. Anderson

en.wikipedia.org

What Schools Are Affiliated With Kenneth C. Anderson ?

Kenneth C. Anderson is affiliated with the following schools:

Kenneth C. Anderson 's Academic­Influence.com Rankings

Why Is Kenneth C. Anderson Influential?

Kenneth C. Anderson 's Published Works

Published Works

Other Resources About Kenneth C. Anderson

What Schools Are Affiliated With Kenneth C. Anderson ?

Kenneth C. Anderson 's AcademicInfluence.com Rankings